

**Centra Inc. and subsidiaries**  
**Consolidated financial statements and**  
**Independent Auditor's Review Report**  
**June 30 ,2025 and 2024**  
**(Stock Code: 3716)**

---

For the convenience of readers and for information purpose only, the auditors' review report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any differences in the interpretation of the two versions, the Chinese-language auditors' review report and financial statements shall prevail.

Centra Inc. and subsidiaries  
June 30 2025 and 2024 Consolidated Financial Report and  
Independent Auditor's Review Report  
Table of Contents

Item	Page
1. Cover	1
2. Table of Contents	2 ~ 3
3. Auditor's Report	4 ~ 6
4. Consolidated Balance Sheet	7 ~ 8
5. Consolidated comprehensive income statements	9 ~ 10
6. Consolidated statement of changes in equity	11
7. Consolidated cash flow statement	12 ~ 13
8. Notes to consolidated financial statement	14 ~ 71
(1) Company history	14
(2) Financial statements approval date and procedure	14
(3) Application of New Standards, Amendments and Interpretations	14 ~ 15
(4) Summary of significant accounting policies	15 ~ 18
(5) Critical accounting judgments, estimates and key sources of assumption uncertainty	18
(6) Summary of significant accounting titles	18 ~ 50
(7) Related party transactions	50 ~ 55
(8) Pledged assets	55

Item	Page
(9) Significant contingent liabilities and unrecognized contractual commitments	55
(10) Significant disaster loss	56
(11) Significant subsequent events	56
(12) Others	56 ~ 68
(13) Notes of disclosure	68~69
(14) Segment information	69 ~ 71

## REPORT ON REVIEW OF FINANCIAL STATEMENTS TRANSLATED FROM CHINESE

To the Board of Directors and Stockholders of Cenra Inc.

### **Introduction**

We have reviewed the accompanying consolidated balance sheets of Cenra and its subsidiaries (the “Group”) as at June 30, 2025 and 2024, and the related consolidated statements of comprehensive income for the three months and six months ended June 30, 2025 and 2024, and the relevant consolidated statements of changes in equity and cash flows for the three months and six months ended June 30, 2025 and 2024, and the relevant notes, including a summary of significant accounting policies (collectively referred to as the “consolidated financial statements”). Management is responsible for the preparation and fair presentation of the financial statements in accordance with the Regulation Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Statement 34 “Interim Financial Reporting” endorsed and issued into effect by the Financial Supervisory Commission. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

### **Scope of Review**

Except as stated in the Basis for Qualified Conclusion paragraph, we conducted the review in accordance with the “Review of Financial Statements” of the Auditing Standard No. 2410. The procedures to be performed when reviewing the consolidated financial statements include inquiry (mainly with the responsible personnel in finance and accounting), analytical procedures and other review procedures. The scope of review work is obviously smaller than the scope of audit work. Therefore, we may not be able to see all the material matters that can be identified through the audit work, so we are not in a position to express an audit opinion.

## **Basis for Qualified Conclusion**

As stated in Note 4(3) to the consolidated financial statements, the financial statements of some non-significant subsidiaries included in the consolidated financial statements as referred to above were not reviewed by us. As of June 30, 2025 and 2024, their total assets were NTD 562,110 thousand and NTD 540,084 thousand, respectively, accounting for 4.55% and 4.30% of the consolidated total assets, respectively; their total liabilities were NTD 374,147 thousand and NTD 278,257 thousand, accounting for 7.53% and 5.44% of the consolidated total liabilities, respectively; their total comprehensive income for the three and six months ended June 30, 2025, and 2024 was a loss of NTD (21,128) thousand, NTD (15,429) thousand, NTD (36,306) thousand and NTD (29,347) thousand, respectively, accounting for 36.46%, (16.35%), (46.62%) and (24.39%) of the consolidated total comprehensive income, respectively. For the for the three and six months ended June 30, 2025 and 2024, the information on the investees recognized under the equity method and the investees disclosed in Note 13 were based on the financial statements of the investees that were prepared during the same period but not reviewed by us. As of June 30, 2025 and 2024, the balance of the investees recognized under the equity method was NTD 490,146 thousand and NTD 490,098 thousand, respectively, accounting for 3.97% and 3.90% of the consolidated total assets, respectively. The share of the profit or loss of the associates and joint ventures recognized under the equity method for the three and six months ended June 30, 2025 and 2024 was NTD 7,199 thousand, NTD 26,565 thousand, NTD 17,157 thousand and NTD 35,773 thousand, respectively, accounting for (12.42%), 28.15%, 22.03% and 29.73% of the consolidated total comprehensive income, respectively.

## **Qualified Conclusion**

According to our review results, we have determined that the foregoing consolidated financial statements have been prepared in all material respects in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the IAS 34 “Interim Financial Reporting” as endorsed and issued into effect by the FSC, and the consolidated financial position of the Group as of June 30, 2025 and 2024, and the consolidated financial performance and consolidated cash flows for the three and six months ended June 30, 2025 and 2024, 2025 and 2024, are presented in a manner that achieves fair presentation.

## Emphasis of matter

As stated in Note 1 to the consolidated financial statements, Cenra Inc. obtained 100% of the shares of CCPC through a share swap. The consideration for the share swap was 0.5 shares of the Company for every 1 share of CCPC. The share swap transaction was completed on September 2, 2024. The above share swap is a reorganization under joint control. As Cenra Inc. is a continuation of CCPC, the consolidated financial statements of CCPC are recognized as relevant assets and liabilities based on the carrying amount of CCPC's consolidated financial statements, and are regarded as the consolidated financial statements of CCPC and its subsidiaries for the comparative period from the beginning of the combination.

Yu, Shu-Fen

Lin, Po-Chuan

---

For and on behalf of PricewaterhouseCoopers, Taiwan

August 8, 2025

-----

The accompanying consolidated financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the review such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying consolidated financial statements and independent auditors' review report are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

As the consolidated financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability

Centra Inc. and subsidiaries  
Consolidated Balance Sheet  
June 30, 2025, December 31 and June 30, 2024

Unit: NTD thousand

	Assets	Additional notes	June 30, 2025		December 31, 2024		June 30, 2024	
			Amount	%	Amount	%	Amount	%
<b>Current assets</b>								
1100	Cash and cash equivalents	6 (1)	\$ 684,064	6	\$ 588,011	5	\$ 451,000	4
1110	Financial assets at fair value through profit and loss- Current	6 (2)	-	-	-	-	44,523	-
1136	Financial assets measured at the amortized cost-current	6 (6)	88,414	1	95,413	1	-	-
1150	Notes receivable-net	6(3)	391,849	3	307,388	2	442,103	4
1160	Notes Receivable-Related Parties- net	7	44,501	-	188,927	1	135,495	1
1170	Notes accounts, net	6(3)	1,471,430	12	1,475,893	12	1,523,244	12
1180	Account receivables-Related Parties- net	7	48,303	1	18,861	-	31,007	-
1200	Other receivables		18,226	-	22,718	-	22,313	-
1210	Other receivables - related parties	7	276,995	2	236,450	2	255,617	2
1220	Current income tax asset		43,567	-	46,728	-	19,667	-
130X	Inventory	6 (4)	2,630,392	21	2,851,044	22	2,518,819	20
1470	Other current assets		82,961	1	64,851	1	70,311	1
11XX	<b>Total current assets</b>		<u>5,780,702</u>	<u>47</u>	<u>5,896,284</u>	<u>46</u>	<u>5,514,099</u>	<u>44</u>
<b>Non-Current assets</b>								
1517	Financial assets fair values through other comprehensive income- non-current	6 (5)	181,419	1	329,968	2	397,974	3
1535	Financial assets at amortized cost-non-current	6 (6)	-	-	-	-	93,013	1
1550	Investment under the equity method	6 (7) and 7	1,452,689	12	1,514,958	12	1,502,536	12
1600	Property, plant, and equipment	6(8) and 8	3,989,000	32	4,077,315	32	4,119,417	33
1755	Right-of-use assets	6 (9)	378,973	3	375,299	3	383,719	3
1760	Investment property	8	110,918	1	117,248	1	55,395	-
1780	Intangible assets		10,873	-	12,421	-	13,891	-
1840	Deferred income tax assets		229,181	2	214,045	2	211,860	2
1900	Other non-current assets	6(10) and 8	218,003	2	232,117	2	264,399	2
15XX	<b>Total of Non-Current Assets</b>		<u>6,571,056</u>	<u>53</u>	<u>6,873,371</u>	<u>54</u>	<u>7,042,204</u>	<u>56</u>
1XXX	<b>Total assets</b>		<u>\$ 12,351,758</u>	<u>100</u>	<u>\$ 12,769,655</u>	<u>100</u>	<u>\$ 12,556,303</u>	<u>100</u>

(Continued on next page)

Cenra Inc. and subsidiaries  
Consolidated Balance Sheet  
June 30, 2025, December 31 and June 30, 2024

Unit: NTD thousand

Liabilities and equity	Additional notes	June 30, 2025		December 31, 2024		June 30, 2024		
		Amount	%	Amount	%	Amount	%	
<b>Current liabilities</b>								
2100	Short-term borrowings	6(11) and 8	\$ 1,879,551	15	\$ 1,381,789	11	\$ 1,254,713	10
2110	Short-term notes payable	6 (12)	377,000	3	88,992	1	666,000	5
2130	Contractual liability- current	6 (20)	32,409	-	31,026	-	19,757	-
2150	Payable notes		-	-	1,208	-	2,718	-
2170	Accounts payable	7	726,719	6	908,706	7	842,828	7
2200	Other payables	6 (13)	811,952	7	756,753	6	758,957	6
2230	Current Tax Liability		68,142	1	54,637	1	42,724	-
2280	Lease liabilities - current		51,002	-	48,023	-	49,008	1
2320	Current portion of long-term liabilities	6(14) and 8	25,200	-	25,200	-	12,600	-
2365	Refund liability –current	6 (20)	73,418	1	94,638	1	96,122	1
2399	Other current liabilities- other		19,128	-	24,668	-	17,925	-
21XX	<b>Total current liabilities</b>		<u>4,064,521</u>	<u>33</u>	<u>3,415,640</u>	<u>27</u>	<u>3,763,352</u>	<u>30</u>
<b>Non-current liabilities</b>								
2540	Long-term borrowings	6(14) and 8	397,700	3	1,290,300	10	809,900	6
2570	Deferred tax liabilities		146,414	1	156,291	1	150,289	1
2580	Lease liabilities – non-current		311,770	3	306,252	2	311,792	3
2600	Other non-current liabilities	6 (9)	46,683	-	51,821	1	79,283	1
25XX	<b>Total of non-current liabilities</b>		<u>902,567</u>	<u>7</u>	<u>1,804,664</u>	<u>14</u>	<u>1,351,264</u>	<u>11</u>
2XXX	<b>Total liabilities</b>		<u>4,967,088</u>	<u>40</u>	<u>5,220,304</u>	<u>41</u>	<u>5,114,616</u>	<u>41</u>
<b>Equity of the parent company</b>								
Capital stock								
3110	Common stock capital	6 (16)	1,490,405	12	1,490,405	12	2,980,811	24
Capital surplus								
3200	Capital surplus	6 (17)	5,882,247	48	5,971,603	47	648,102	6
Retained earnings								
3310	Legal reserve	6 (18)	11,362	-	-	-	811,652	6
3320	Special reserve		222,767	2	188,958	1	188,958	1
3350	Unappropriated earnings		112,229	1	113,624	1	2,981,398	24
Other equity								
3400	Other equity	6 (19)	( 248,273)	( 2)	( 222,767)	( 2)	( 180,416)	( 2)
3500	Treasury stock	6 (16)	( 125,932)	( 1)	( 32,304)	-	( 28,054)	-
31XX	<b>Equity attributable to owners of the parent Company</b>		<u>7,344,805</u>	<u>60</u>	<u>7,509,519</u>	<u>59</u>	<u>7,402,451</u>	<u>59</u>
36XX	<b>Non-controlling interest</b>		<u>39,865</u>	<u>-</u>	<u>39,832</u>	<u>-</u>	<u>39,236</u>	<u>-</u>
3XXX	<b>Total equity</b>		<u>7,384,670</u>	<u>60</u>	<u>7,549,351</u>	<u>59</u>	<u>7,441,687</u>	<u>59</u>
Significant contingent liabilities and unrecognized contractual commitments								
Significant subsequent events								
3X2X	<b>Total Liabilities and Equity</b>		<u>\$ 12,351,758</u>	<u>100</u>	<u>\$ 12,769,655</u>	<u>100</u>	<u>\$ 12,556,303</u>	<u>100</u>

The accompanying notes are an integral part of these consolidated financial statements.

Chairman: Wang Ming-Ning Memorial Foundation      President: Wang, Hou-Kai      Accounting Supervisor: Hsiao, Hui-Wen  
Representative: Wang Hsieh, I-Chen

Cenra Inc. and subsidiaries  
Consolidated comprehensive income statements  
January 1 to June 30, 2025 and 2024

Unit: NTD thousand  
(except EPS in NTD)

Item	Additional notes	April 1 to June 30, 2025		April 1 to June 30, 2024		January 1 to June 30, 2025		January 1 to June 30, 2024		
		Amount	%	Amount	%	Amount	%	Amount	%	
4000	Operating revenues	6(20) and 7	\$ 2,107,036	100	\$ 2,215,722	100	\$ 4,362,664	100	\$ 4,499,748	100
5000	Operating cost	6 (4)								
		(24) and 7	( 1,304,404)	( 62)	( 1,386,236)	( 63)	( 2,660,524)	( 61)	( 2,806,946)	( 63)
5950	Operating gross profit		802,632	38	829,486	37	1,702,140	39	1,692,802	37
	Operating expenses	6 (24)								
6100	Selling and marketing expenses		( 493,670)	( 23)	( 516,737)	( 23)	( 1,028,778)	( 24)	( 1,059,443)	( 24)
6200	General and Administrative expenses		( 87,303)	( 4)	( 117,994)	( 5)	( 195,168)	( 4)	( 203,033)	( 4)
6300	Research and development expenses		( 116,461)	( 6)	( 127,103)	( 6)	( 246,871)	( 6)	( 240,134)	( 5)
6450	Expected credit impairment gain	12 (2)	595	-	4,911	-	22,534	1	5,672	-
6000	Total operating expenses		( 696,839)	( 33)	( 756,923)	( 34)	( 1,448,283)	( 33)	( 1,496,938)	( 33)
6900	Operating income		105,793	5	72,563	3	253,857	6	195,864	4
	Non-operating revenues and expenses									
7100	Interest income	6(21) and 7	2,881	-	2,941	-	5,198	-	5,024	-
7010	Other income	6 (22)	9,602	1	7,991	1	14,773	-	17,858	1
7020	Other profits and losses	6 (23)	( 4,861)	-	( 2,081)	-	( 3,890)	-	( 4,502)	-
7050	Financial costs	6 (9)								
		(25)	( 15,347)	( 1)	( 15,305)	( 1)	( 31,172)	( 1)	( 31,818)	( 1)
7060	Shareholding in the affiliated companies and joint ventures under the equity method	6 (7)	( 14,252)	( 1)	29,256	1	( 7,321)	-	44,880	1
7000	Total non-operating revenues and expenses		( 21,977)	( 1)	22,802	1	( 22,412)	( 1)	31,442	1
7900	Income before income tax		83,816	4	95,365	4	231,445	5	227,306	5
7950	Income tax expenses	6 (26)	( 36,670)	( 2)	( 14,696)	-	( 66,084)	( 1)	( 40,035)	( 1)
8200	Net income		\$ 47,146	2	\$ 80,669	4	\$ 165,361	4	\$ 187,271	4

(Continued on next page)

Cenra Inc. and subsidiaries  
Consolidated comprehensive income statements  
January 1 to June 30, 2025 and 2024

Unit: NTD thousand  
(except EPS in NTD)

Item	Additional notes	April 1 to June 30, 2025		April 1 to June 30, 2024		January 1 to June 30, 2025		January 1 to June 30, 2024	
		Amount	%	Amount	%	Amount	%	Amount	%
<b>Other comprehensive profit or loss (net)</b>									
<b>The items that are not re-classified as profit or loss</b>									
8316	Unrealized valuation gains and losses on Investment of equity instruments at fair value through other comprehensive income	6 (5)(19)							
		(\$ 2,232)	-	\$ 5,949	-	(\$ 5,470)	-	(\$ 91,713)	( 2)
8310	Total amount of items not reclassified to profit or income	( 2,232)	-	5,949	-	( 5,470)	-	( 91,713)	( 2)
<b>Items that may be re-classified subsequently under profit or loss</b>									
8361	Exchange differences from the translation of financial statements of foreign operations	6 (19)							
		( 127,946)	( 6)	9,485	-	( 101,955)	( 2)	30,890	1
8370	The proportion of other comprehensive incomes from associates, and equity joint-ventures accounted for under the equity method – may be reclassified as profit and loss.	6 (19)							
		( 498)	-	154	-	( 453)	-	45	-
8399	Income tax related to items possibly be reclassified	6 (19) (26)							
		25,589	1	( 1,897)	-	20,391	-	( 6,178)	-
8360	Total amount of items probably reclassified to profit or loss subsequently	( 102,855)	( 5)	7,742	-	( 82,017)	( 2)	24,757	1
8300	<b>Other comprehensive profit or loss (net)</b>	(\$ 105,087)	( 5)	\$ 13,691	-	(\$ 87,487)	( 2)	(\$ 66,956)	( 1)
8500	<b>Current period other comprehensive income (Gross)</b>	(\$ 57,941)	( 3)	\$ 94,360	4	\$ 77,874	2	\$ 120,315	3
Net income (loss) attributable to:									
8610	Owners of parent	\$ 47,334	2	\$ 80,253	4	\$ 165,328	4	\$ 186,086	4
8620	Non-controlling interest	( 188)	-	416	-	33	-	1,185	-
		\$ 47,146	2	\$ 80,669	4	\$ 165,361	4	\$ 187,271	4
Total comprehensive income attributable to:									
8710	Owners of parent	(\$ 57,753)	( 3)	\$ 93,944	4	\$ 77,841	2	\$ 119,130	3
8720	Non-controlling interest	( 188)	-	416	-	33	-	1,185	-
		(\$ 57,941)	( 3)	\$ 94,360	4	\$ 77,874	2	\$ 120,315	3
Earnings per share									
9750	Basic earnings per share	6 (27)							
		\$ 0.38		\$ 0.54		\$ 1.31		\$ 1.25	
9850	Diluted earnings per share	\$ 0.38		\$ 0.54		\$ 1.31		\$ 1.25	

The accompanying notes are an integral part of these consolidated financial statements.

Chairman: Wang Ming-Ning Memorial Foundation  
Representative: Wang Hsieh, I-Chen

President: Wang, Hou-Kai

Accounting Supervisor: Hsiao, Hui-Wen

Cenra Inc. and subsidiaries  
Consolidated statement of changes in equity  
January 1 to June 30, 2025 and 2024

Unit: NTD thousand

	Additional notes	Equity of the parent company											Non-controlling interest	Total equity
		Capital surplus			Retained earnings			Other equity			Total			
		Common stock capital	Issuance premium	Treasury stock trade	Others	Legal reserve	Special reserve	Unappropriated earnings	Exchange differences from the translation of financial statements of foreign operations	Unrealized gain or loss on financial assets at fair value through other comprehensive profit or loss		Treasury stock		
<b>January 1 to June 30, 2024</b>														
Balance at January 1, 2024		\$ 2,980,811	\$ 578,416	\$ 67,842	\$ 1,844	\$ 777,269	\$ 188,958	\$ 3,012,349	(\$ 116,566)	(\$ 30,507)	(\$ 28,054)	\$ 7,432,362	\$ 38,051	\$ 7,470,413
Net income		-	-	-	-	-	-	186,086	-	-	-	186,086	1,185	187,271
Current period other comprehensive income	6 (5)(19)	-	-	-	-	-	-	-	24,757	( 91,713 )	-	( 66,956 )	-	( 66,956 )
Current period other comprehensive income (Gross)		-	-	-	-	-	-	186,086	24,757	( 91,713 )	-	119,130	1,185	120,315
Appropriations of 2023 retained earnings	6 (18)													
Legal reserve		-	-	-	-	34,383	-	( 34,383 )	-	-	-	-	-	-
Cash dividends		-	-	-	-	-	-	( 149,041 )	-	-	-	( 149,041 )	-	( 149,041 )
Equity instrument at fair value through other comprehensive income statement	6 (5)(19)	-	-	-	-	-	-	( 33,613 )	-	33,613	-	-	-	-
Balance at June 30, 2024		\$ 2,980,811	\$ 578,416	\$ 67,842	\$ 1,844	\$ 811,652	\$ 188,958	\$ 2,981,398	(\$ 91,809)	(\$ 88,607)	(\$ 28,054)	\$ 7,402,451	\$ 39,236	\$ 7,441,687
<b>January 1 to June 30, 2025</b>														
Balance at January 1, 2025		\$ 1,490,405	\$ 5,901,560	\$ 68,087	\$ 1,956	\$ -	\$ 188,958	\$ 113,624	(\$ 85,170)	(\$ 137,597)	(\$ 32,304)	\$ 7,509,519	\$ 39,832	\$ 7,549,351
Net income		-	-	-	-	-	-	165,328	-	-	-	165,328	33	165,361
Current period other comprehensive income	6 (5)(19)	-	-	-	-	-	-	-	( 82,017 )	( 5,470 )	-	( 87,487 )	-	( 87,487 )
Current period other comprehensive income (Gross)		-	-	-	-	-	-	165,328	( 82,017 )	( 5,470 )	-	77,841	33	77,874
Appropriations of 2024 retained earnings	6 (18)													
Legal reserve		-	-	-	-	11,362	-	( 11,362 )	-	-	-	-	-	-
Special reserve		-	-	-	-	-	33,809	( 33,809 )	-	-	-	-	-	-
Cash dividends		-	-	-	-	-	-	( 59,571 )	-	-	-	( 59,571 )	-	( 59,571 )
Distribution of cash dividends from capital reserve	6 (18)	-	( 89,356 )	-	-	-	-	-	-	-	-	( 89,356 )	-	( 89,356 )
Repurchase of treasury stock	6 (16)	-	-	-	-	-	-	-	-	-	( 93,628 )	( 93,628 )	-	( 93,628 )
Equity instrument at fair value through other comprehensive income statement	6 (5)(18)(19)	-	-	-	-	-	-	( 61,981 )	-	61,981	-	-	-	-
Balance at June 30, 2025		\$ 1,490,405	\$ 5,812,204	\$ 68,087	\$ 1,956	\$ 11,362	\$ 222,767	\$ 112,229	(\$ 167,187)	(\$ 81,086)	(\$ 125,932)	\$ 7,344,805	\$ 39,865	\$ 7,384,670

The accompanying notes are an integral part of these consolidated financial statements.

Chairman: Wang Ming-Ning Memorial Foundation  
Representative: Wang Hsieh, I-Chen

President r: Wang, Hou-Kai

Accounting Supervisor: Hsiao, Hui-Wen

Centra Inc. and subsidiaries  
Consolidated cash flow statement  
January 1 to June 30, 2025 and 2024

Unit: NTD thousand

	Additional notes	January 1 to June 30, 2025	January 1 to June 30, 2024
<u>Cash flow from operating activities</u>			
Current year net profit before taxation		\$ 231,445	\$ 227,306
Adjustments			
Profits and loss			
Depreciation expenses	6 (23) (24)	168,509	176,580
Amortization expenses	6 (24)	5,323	6,085
Expected credit impairment gain	12 (2)	( 22,534 )	( 5,672 )
Decrease of allowance for sales return and allowance		( 3,162 )	( 1,083 )
Interest expenses	6 (25)	31,172	31,818
Interest income	6 (21)	( 5,198 )	( 5,024 )
Dividend income	6 (5)(22)	( 2,280 )	-
Net gain on financial assets at fair value through profit or loss	6 (23)	-	( 890 )
Shareholding in the affiliated companies and joint ventures under the equity method	6 (7)	7,321	( 44,880 )
Gain in disposal of real estate, plant buildings, equipment & facilities	6 (23)	( 571 )	( 27 )
Changes in assets/liabilities relating to operating activities			
Net changes in assets relating to operating activities			
Financial assets at fair value through profit and loss		-	2,043
Notes receivable (including related party and non-related party)		59,965	14,119
Accounts receivable (including related party and non-related party)		( 27,344 )	16,204
Other account receivable- (including related party and non-related party)		23,699	10,601
Inventory		213,993	67,400
Other current assets		( 18,110 )	( 19,726 )
Net changes in liabilities relating to operating activities			
Contractual liability- current		1,383	( 28,172 )
Payable notes		( 1,208 )	190
Accounts payable		( 179,487 )	( 19,571 )
Other payables		( 79,616 )	5,147
Refund liability - current		( 25,526 )	15,037
Other current liabilities- other		( 1,034 )	( 2,093 )
Other non-current liabilities		( 382 )	( 25,421 )
Cash inflow from operating activities		376,358	419,971
Interest received		3,839	3,656
Interest paid		( 31,996 )	( 32,909 )
Income tax paid		( 62,391 )	( 60,628 )
Income tax refund		4,497	2,337
Dividends received		54,722	68,694
Net cash inflow from operating activities		345,029	401,121

(Continued on next page)

Centra Inc. and subsidiaries  
Consolidated cash flow statement  
January 1 to June 30, 2025 and 2024

Unit: NTD thousand

	<u>Additional notes</u>	<u>January 1 to June 30, 2025</u>	<u>January 1 to June 30, 2024</u>
<u>Cash flow from investing activities</u>			
Increase of the financing amount receivable		(\$ 41,000)	\$ -
Acquisition of financial assets at fair value through other comprehensive profit or loss	6 (5)	( 97)	-
Value of disposal of financial assets measured at FVTOCI	6 (5)	139,653	119,717
Acquisition of investment under the equity method	7	( 463)	-
Refund of investment under equity method	6 (7) and 7	-	25,349
Purchase of property, plant, and equipment	6 (28)	( 76,974)	( 190,529)
Proceeds from disposal of property, plant and equipment		681	770
Purchase of intangible assets		( 116)	-
Decrease (increase) in guarantee deposits paid		( 7,795)	13,281
Increase of other non-current assets		( 1,425)	( 19,269)
Net cash inflow (outflow) from investing activities		<u>12,464</u>	<u>( 50,681)</u>
<u>Cash flow from financing activities</u>			
Increase (decrease) in Short-term borrowings	6 (29)	497,762	( 264,800)
Increase of short-term notes payable	6 (29)	288,008	555,116
Lease principal repayment	6 (29)	( 24,414)	( 21,919)
Current borrowing amount of long-term loan	6 (29)	140,000	320,000
Current repaying amount of long-term loan	6 (29)	( 1,032,600)	( 946,500)
Decrease (increase) in guarantee deposits received	6 (29)	( 2,396)	5,456
Repurchase of treasury stock	6 (16)	( 93,628)	-
Net cash outflow from financing activities		<u>( 227,268)</u>	<u>( 352,647)</u>
Impact of changes in exchange rate on cash and cash equivalents		( 34,172)	8,491
Current cash and cash equivalents increase		96,053	6,284
Balance of cash and cash equivalents, beginning of period		588,011	444,716
Balance of cash and cash equivalent, end of period		<u>\$ 684,064</u>	<u>\$ 451,000</u>

The accompanying notes are an integral part of these consolidated financial statements.

Chairman: Wang Ming-Ning Memorial Foundation  
Representative: Wang Hsieh, I-Chen

President: Wang, Hou-Kai

Accounting Supervisor: Hsiao, Hui-Wen

Centra Inc. and subsidiaries  
Notes to consolidated financial statement  
Q2 2025 and 2024

Unit: NTD thousand  
(Except where otherwise stated)

1. Company history

- (1) Centra Inc. was established on September 2, 2024 and listed on TWSE on the same day.
- (2) On May 28, 2024, China Chemical & Pharmaceutical Co., Ltd. (hereinafter referred to as “CCPC”) resolved to apply for the establishment of the Company at the shareholders’ meeting and the meeting of the Company’s founders. The Company acquired 100% of the equity of CCPC through a share swap. The consideration for the share swap was 0.5 shares of the Company for every 1 share of CCPC. The Company completed the share swap transaction on September 2, 2024. CCPC became a wholly owned subsidiary of the Company and ceased its listing and public offering. The Company’s common stock shares are listed on the Taiwan Stock Exchange (TWSE) on the same day with the stock code of “3716.”
- (3) The Company and its subsidiary (hereinafter referred to as “The Group”) have major business in manufacturing and selling pharmaceutical products and health products, as well as the import business of related medical appliances.

2. Financial statements approval date and procedure

These consolidated financial statements were authorized by the Board of Directors on August 8, 2025.

3. Application of New Standards, Amendments and Interpretations

- (1) Effect of the adoption of new issuances of or amendments to International Financial Reporting Standards (“IFRS”) as endorsed and issued into effect by the Financial Supervisory Commission (“FSC”)

The new publication, amendments, and revision of the 2025 International Financial Reporting Standards (IFRS) that was endorsed and issued into effect by the Financial Supervisory Commission are as follows:

<u>New releases / amendments / revisions of the Standards and Interpretations</u>	<u>The effective date announced by the International Accounting Standards Board</u>
<u>Amendments to IAS No. 21 "Lack of Exchangeability"</u>	<u>January 1, 2025</u>

The Group has assessed the aforementioned standards, interpretations, and interpretative announcements and has concluded that they have no material impact on the Group’s financial position and financial performance.

- (2) Effect of new issuances of or amendments to IFRS as endorsed by the FSC but not yet adopted by the Company and subsidiaries

The new publication, amendments, and revision of the 2026 International Financial Reporting Standards (IFRS) that was recognized by the Financial Supervisory Commission are as follows:

New releases / amendments / revisions of the Standards and Interpretations	The effective date announced by the International Accounting Standards Board
Amendments to IFRIS 9 and IFRS 7 “Amendments to the Classification and Measurement of Financial Instruments”	January 1, 2026
Amendments to IFRS 9 and IFRS 7, “Contracts Referencing Nature-dependent Electricity”	January 1, 2026
IFRS 17 “Insurance Contracts”	January 1, 2023
Amendments to IFRS 17 “Insurance Contracts”	January 1, 2023
Amendments to IFRS 17 - Application of IFRS 17 and IFRS 9 — Comparative Information	January 1, 2023
Annual Improvements to IFRSs—Volume 11	January 1, 2026

The Group has assessed the aforementioned standards, interpretations, and interpretative announcements and has concluded that they have no material impact on the Group’s financial position and financial performance.

(3) IFRS issued by IASB but not yet endorsed by the FSC

The newly released, revised and amended IFRS standards and interpretations by the IASB but not yet recognized by the FSC are summarized as follows:

New releases / amendments / revisions of the Standards and Interpretations	The effective date announced by the International Accounting Standards Board
Amendment to IFRS 10 and IAS 28 “The Assets Sales or Purchase between Investors and Their Affiliates or Joint Ventures”	To be determined by the “International Accounting Standards Board (IASB).”
IFRS 18 “Presentation and Disclosure in Financial Statements”	January 1, 2027
IFRS 19 “Subsidiaries without Public Accountability: Disclosures”	January 1, 2027

Except for the following statements, the Group has assessed the aforementioned standards, interpretations, and interpretative announcements and has concluded that they have no material impact on the Group’s financial position and financial performance:

IFRS 18 “Presentation and Disclosure in Financial Statements”

IFRS 18 “Presentation and Disclosure in Financial Statements” has replaced IAS 1, updating the structure of the statement of comprehensive income, and adding the disclosure of management performance measurements, while strengthening the summary and division of the use in the main financial statements and notes.

4. Summary of significant accounting policies

The significant accounting policies, except for the statement of compliance, the basis of preparation, the basis of consolidation, and the new parts are as follows, which are the same as Note 4 to the consolidated financial statements of 2024. These policies have been consistently applied to all the period presented, unless otherwise stated.

(1) Compliance Statement

1. These consolidated financial statements are prepared in accordance with the “Regulations Governing the Preparation of Financial Reports by Securities Issuers” and the International Accounting Standards and IAS 34 “Interim Financial Reporting”.
2. The consolidated financial statements shall be read together with the 2024 consolidated financial statements.

(2) Basis of preparation

1. Except for the following items, these consolidated statements have been prepared under the historical cost convention:
  - (1) Financial assets measured at fair value through profit or loss (including derivatives).
  - (2) Financial assets at fair value through other comprehensive income
  - (3) Defined benefit assets and liabilities recognized at the net amount of pension fund assets less the present value of defined benefit obligations.
2. The financial statements prepared in accordance with the International Financial Reporting Standards, international accounting standards, interpretation and interpretation notice (referred to as “IFRS” hereinafter) that is endorsed and issued into effect by the FSC requires the use of some critical accounting estimates; also, the judgment by the management is required while using the Group’s accounting policies. Please refer to Note 5 for the items involving extensive judgment or complexity, or significant assumptions and estimates related to the consolidated financial statements.

(3) Basis of consolidation

The basis of preparation for consolidated financial statements

The preparation principles of the consolidated financial statements are the same as those of the 2024 consolidated financial statements.

2. Subsidiaries included in the financial statements:

Investor	Name of the subsidiary	Nature of the operation	Percentage of shareholdings (%)			Remarks
			June 30, 2025	December 31, 2024	June 30, 2024	
Cenra Inc.	China Chemical & Pharmaceutical Co., Ltd. (CCPC)	Manufacture and sales of Western medicine preparations and health-care articles.	100.00	100.00	-	Note 2
Cenra Inc.	Chunghwa Yuming Healthcare Co., Ltd. (Chunghwa Yuming)	Wholesale of medicine and medical equipment	100.00	-	-	Note 5
Cenra Inc.	Providence Investments Inc.	General investment businesses	100.00	-	-	Note 1 and Note 4
China Chemical & Pharmaceutical Co., Ltd.	Chunghwa Yuming Healthcare Co., Ltd. (Chunghwa Yuming)	Wholesale of medicine and medical equipment	-	100.00	100.00	Note 5
China Chemical & Pharmaceutical Co., Ltd.	Chunghwa Senior Lifestyle Services Co. Ltd. (Chunghwa Senior Lifestyle Services)	Medicine, wholesale of medicine equipment and home care service	100.00	100.00	98.40	Note 1
China Chemical & Pharmaceutical Co., Ltd.	Chunghwa Holding Co.,Ltd. (Chunghwa)	Professional investment company	100.00	100.00	100.00	
China Chemical &	Tairung Enterprise	Manufacture and	71.64	71.64	71.64	Note 1

Investor	Name of the subsidiary	Nature of the operation	Percentage of shareholdings (%)			Remarks
			June 30, 2025	December 31, 2024	June 30, 2024	
Pharmaceutical Co., Ltd.	Co., Ltd. (Tairung)	sales of glass, plastics made containers				
Chunghwa Yuming Healthcare Co., Ltd.	Chunghwa Biomedical Technology Corp.	Manufacturer of cleaning products	75.23	75.23	73.96	Note 1
Chunghwa Holding Co., Ltd.	Suzhou Chung-hwa Chemical&pharmaceutical Industrial Co., Ltd. (SCCPC)	Manufacture and sales of pharmaceutical medicine and health products.	100.00	100.00	100.00	
Suzhou Chung-hwa Chemical&pharmaceutical Industrial Co., Ltd.	Suzhou Chunghwa Yuming Pharmaceutical Co., Ltd.	Wholesale and sales of pharmaceutical medicine and medical equipment.	100.00	100.00	100.00	Note 1
Suzhou Chung-hwa Chemical&pharmaceutical Industrial Co., Ltd.	Shanghai Yuhou Trading Co., Ltd. (formerly known as Pei Fu (Shanghai) Co., Ltd.)	Wholesale and sales of medical equipment.	100.00	100.00	100.00	Note 1
Suzhou Chung-hwa Chemical&pharmaceutical Industrial Co., Ltd.	Suzhou Chung-Hwa Le Huo Jian Kang Co., Ltd.	E-commerce sales of health products	100.00	100.00	100.00	Note 1
Suzhou Chung-hwa Chemical&pharmaceutical Industrial Co., Ltd.	Chung-Hwa Le Huo Jian Kang (HK) Co., Ltd.	Biotech products sold as an agent	100.00	100.00	100.00	Note 3

Note 1: Due to the definition of the significant subsidiaries, their financial statements of June 30, 2025 and 2024 were not reviewed by the CPAs.

Note 2: The Company was established on September 2, 2024, and acquired 100% of the equity of CCPC through a share swap, making the Company the ultimate parent company of the Group. As the organization is a joint control entity, the Group deems it as a combination of CCPC and its subsidiaries from the beginning, and has prepared the consolidated financial statements for the comparative period.

Note 3: Chung-Hwa Le Huo Jian Kang (HK) Co., Ltd. not yet invested capital as of June 30, 2025.

Note 4: Providence Investments was established on June 5, 2025

Note 5: On June 30, 2025, CCPC was reorganized and restructured, with Cenra holding 100% shares held of Chunghwa Yuming Healthcare.

3. Subsidiary company not included in the consolidated financial statements are as follows: Not applicable.
4. Adjustments on subsidiary companies with different accounting periods: Not applicable.
5. Significant limitations: Not applicable.
6. Subsidiaries over which the group has significant influence but not control: none

#### (4) Employee benefits

##### Pension - defined benefit plan

The interim pension cost is calculated based on the actuarial pension cost rate on the last day of

the previous fiscal year from the beginning of the year to the end of the period. If there is a significant market change, significant reduction, settlement, or other significant one-time event after the end date, it is adjusted and the relevant information is correspondingly disclosed.

(5) Income tax

The average effective tax rate used to estimate the interim income tax expense shall be applicable to the interim income before tax, and the relevant information is correspondingly disclosed.

5. Critical accounting judgments, estimates and key sources of assumption uncertainty

There is no significant change in the current period. Please refer to Note 5 to the 2024 consolidated financial statements.

6. Summary of significant accounting titles

(1) Cash and cash equivalents

	<u>June 30, 2025</u>	<u>December 31, 2024</u>	<u>June 30, 2024</u>
Cash on hand	\$ 4,173	\$ 3,934	\$ 4,076
Check deposit and demand deposit	633,059	530,341	446,924
Cash equivalents- time deposits	<u>46,832</u>	<u>53,736</u>	<u>-</u>
	<u>\$ 684,064</u>	<u>\$ 588,011</u>	<u>\$ 451,000</u>

1. The financial institutions that the Group deals with are with good credit quality; also, the Group deals with a number of financial institutions to diversify credit risk; therefore, the possibility of default is very unlikely.

2. None of the Group's cash and cash equivalents pledged to others as collateral.

(2) Financial assets at fair value through profit and loss

<u>Item</u>	<u>June 30, 2025</u>	<u>December 31, 2024</u>	<u>June 30, 2024</u>
Current items:			
Financial assets mandatorily measured at fair value through profit or loss			
Beneficiary certificate	\$ -	\$ -	\$ 44,440
Evaluation adjustment	<u>-</u>	<u>-</u>	<u>83</u>
	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 44,523</u>

1. The details of the financial assets measured at fair value through profit or loss recognized in profit or loss are as follows:

	April 1 to June 30, 2025	April 1 to June 30, 2024
Financial assets mandatorily measured at fair value through profit or loss		
Beneficiary certificate	\$ -	\$ 339
Mixed instruments (Note)	-	41
	<u>\$ -</u>	<u>\$ 380</u>
	April 1 to June 30, 2025	April 1 to June 30, 2024
Financial assets mandatorily measured at fair value through profit or loss		
Beneficiary certificate	\$ -	\$ 841
Mixed instruments (Note)	-	49
	<u>\$ -</u>	<u>\$ 890</u>

Note: The subsidiary, Suzhou Chung-Hwa, signed a 1-month RMB structured deposit agreement with a bank in March 2024 for a sum of RMB 22,040 (RMB 5,000 thousand). As the structured deposit was included in derivatives and the main contract was an asset within the scope of IFRS 9, the entire hybrid contract was classified as a financial asset measured at fair value through profit or loss. The structured deposit expired in April 2024.

2. No financial asset at fair value through profit or loss was pledged by the Group for loan guarantee.

(3) Note receivable and accounts receivable

	June 30, 2025	December 31, 2024	June 30, 2024
Notes receivable	\$ 392,664	\$ 308,368	\$ 443,317
Less: Allowance for losses	( 815)	( 980)	( 1,214)
	<u>\$ 391,849</u>	<u>\$ 307,388</u>	<u>\$ 442,103</u>
Accounts receivable	\$ 1,613,800	\$ 1,617,103	\$ 1,653,228
Less: Allowance for sales and discount	( 133,199)	( 130,037)	( 123,741)
Less: Allowance for losses	( 9,171)	( 11,173)	( 6,243)
	<u>\$ 1,471,430</u>	<u>\$ 1,475,893</u>	<u>\$ 1,523,244</u>

1. The aging analysis of accounts receivable and bill receivable is as follows:

	June 30, 2025		December 31, 2024	
	Accounts receivable	Notes receivable	Accounts receivable	Notes receivable
Not-overdue	\$ 1,581,752	\$ 392,182	\$ 1,595,090	\$ 308,368
Overdue within 1-90 days	21,372	482	18,550	-
Overdue within 91-180 days	7,868	-	2,925	-
Overdue exceeding 181 days	2,808	-	538	-
	<u>\$ 1,613,800</u>	<u>\$ 392,664</u>	<u>\$ 1,617,103</u>	<u>\$ 308,368</u>

	June 30, 2024	
	Accounts receivable	Notes receivable
Not-overdue	\$ 1,636,536	\$ 443,317
Overdue within 1-90 days	14,381	-
Overdue within 91-180 days	1,549	-
Overdue exceeding 181 days	762	-
	<u>\$ 1,653,228</u>	<u>\$ 443,317</u>

The aforementioned aging analysis is based on the overdue days.

- Account and note receivables as of June 30, 2025, December 31 and June 30, 2024 were from customer contracts. Account receivables (including note receivables) and the associated allowed made stood at NTD 1,974,670 and NTD 8,597, respectively, on January 1, 2024.
- The exposure amounts of the maximum credit risk which can represent the accounts receivable and bill receivable of the Group without considering the possessed collateral or other credit enhancement condition on June 30, 2025, December 31 and June 30, 2024 are its book amount.
- The accounts receivable listed in the account of the Group does not possess any collateral.
- Please find Note 12 (2) for the relevant explanation about credit risk.

(4) Inventory

June 30, 2025			
	Cost	Allowance for loss from price declination	Book value
Raw materials	\$ 958,247	(\$ 14,467)	\$ 943,780
Material	180,108	( 2,835)	177,273
Work in process	344,474	( 402)	344,072
Finished products	586,068	( 29,047)	557,021
Merchandise inventory	634,089	( 25,843)	608,246
	<u>\$ 2,702,986</u>	<u>(\$ 72,594)</u>	<u>\$ 2,630,392</u>

December 31, 2024			
	Cost	Allowance for loss from price declination	Book value
Raw materials	\$ 954,277	(\$ 8,537)	\$ 945,740
Material	175,599	( 1,278)	174,321
Work in process	341,734	( 433)	341,301
Finished products	737,246	( 33,195)	704,051
Merchandise inventory	727,165	( 41,534)	685,631
	<u>\$ 2,936,021</u>	<u>(\$ 84,977)</u>	<u>\$ 2,851,044</u>

June 30, 2024			
	Cost	Allowance for loss from price declination	Book value
Raw materials	\$ 940,374	(\$ 19,518)	\$ 920,856
Material	164,585	( 5,052)	159,533
Work in process	310,128	( 2,366)	307,762
Finished products	630,898	( 22,795)	608,103
Merchandise inventory	572,334	( 49,769)	522,565
	<u>\$ 2,618,319</u>	<u>(\$ 99,500)</u>	<u>\$ 2,518,819</u>

The cost of inventory recognized as expense of The Group within the current period:

	April 1 to June 30, 2025	April 1 to June 30, 2024
Cost of inventory sold	\$ 1,279,829	\$ 1,351,143
Labor service cost	29,378	28,194
Loss on inventory falling price (gain from price recovery)	( 7,656)	5,662
Inventory disposition losses	2,853	1,237
	<u>\$ 1,304,404</u>	<u>\$ 1,386,236</u>
	January 1 to June 30, 2025	January 1 to June 30, 2024

Cost of inventory sold	\$	2,610,765	\$	2,738,093
Labor service cost		57,227		55,873
Loss on inventory falling price (gain from price recovery)	(	11,770)		11,229
Inventory disposition losses		<u>4,302</u>		<u>1,751</u>
	\$	<u>2,660,524</u>	\$	<u>2,806,946</u>

For the three months and the six months ended June 30, 2025 and 2024, as the market prices of some of the Group's inventory recovered and the inventories that had been recognized in depreciation losses in prior years were scrapped, it was recognized in gain from price recovery.

(5) Financial assets at fair value through other comprehensive profit or loss

Item	June 30, 2025	December 31, 2024	June 30, 2024
Non-current items:			
Equity instruments			
Listed and emerging stocks	\$ 187,593	\$ 389,227	\$ 413,132
Non-listed shares	<u>59,069</u>	<u>58,971</u>	<u>58,971</u>
	246,662	448,198	472,103
Evaluation adjustment	<u>(65,243)</u>	<u>(118,230)</u>	<u>(74,129)</u>
	<u>\$ 181,419</u>	<u>\$ 329,968</u>	<u>\$ 397,974</u>

1. The Group decides to classify the stock of strategic as investment financial assets at fair value through other comprehensive income and the fair value of that investment on June 30, 2025, December 31 and June 30, 2024 are its book amount.
2. The Group sold its stock investment at fair value of NTD 0, NTD 119,717, NTD 139,653 and NTD 119,717 for the three months and the six months ended June 30, 2025 and 2024, respectively, and recognized the capital gain from disposal in aggregate as retained earnings amounting to NTD 0, NTD (33,613), NTD (61,981) and NTD (33,613), respectively.
3. The Group purchased equity instruments for an investment amounts of NTD 97 and NTD 0 for the six months ended June 30, 2025 and 2024, respectively.
4. The details of financial assets at fair value through other comprehensive income which recognized in income and comprehensive income are as follows:

Item	April 1 to June 30, 2025	April 1 to June 30, 2024
<u>Equity instruments</u>		
Recognized in comprehensive income of changes in fair value.	(\$ 2,232)	\$ 5,949
The accumulated profits change to retained earnings due to de-recognition (post-tax profit or loss)	\$ -	(\$ 33,613)
Recognized as dividend in income in profit The party still in possession at the end of this term	\$ 2,280	\$ -

Item	January 1 to June 30, 2025	January 1 to June 30, 2024
<u>Equity instruments</u>		
Recognized in comprehensive income of changes in fair value.	(\$ 5,470)	(\$ 91,713)
The accumulated losses change to retained earnings due to de-recognition (post-tax profit or loss)	(\$ 61,981)	(\$ 33,613)
Recognized as dividend in income in profit The party still in possession at the end of this term	\$ 2,280	\$ -

(6) Financial assets measured at the amortized cost

Item	June 30, 2025	December 31, 2024	June 30, 2024
Current items:			
Time deposits	\$ 88,414	\$ 95,413	\$ -
Non-current items:			
Time deposits	\$ -	\$ -	\$ 93,013

1. Financial assets measured on the basis of amortized cost is recognized as income and specified as follows:

	April 1 to June 30, 2025	April 1 to June 30, 2024
Interest income	\$ 660	\$ 691
	January 1 to June 30, 2025	January 1 to June 30, 2024
Interest income	\$ 1,359	\$ 1,368

2. In the absence of collateral or other credit enhancement, the maximum amount of credit risk exposure of the symbolic financial assets measured on the basis of amortized cost held by the Group was NTD 88,414, NTD 95,413 and NTD 93,013, respectively as of June 30, 2025, December 31 and June 30, 2024.
3. The Group did not pledge any financial assets measured on the basis of amortized cost under lien.
4. For additional information on the financial assets measured on the basis of amortized cost, refer to Note 12, (2). The Group invests the certificates of deposits only with financial institutions in good credit standing. Default is unlikely to occur.

(7) Investment under the equity method

Name of investee	June 30, 2025	December 31, 2024	June 30, 2024
Affiliated enterprises:			
Chunghwa Chemical Synthesis & Biotech Co., Ltd. (CCSB)	\$ 962,543	\$ 987,475	\$ 1,012,438
Sino-Japan Chemical Co., Ltd. (Sino-Japan Chemical)	486,162	519,603	476,553
PHERMPEP CO., LTD. (PHERMPEP)	2,093	3,960	9,617
Wuxi Jirui Medical Technology Co., Ltd. (Wuxi Jirui)	1,891	3,920	3,928
	\$ 1,452,689	\$ 1,514,958	\$ 1,502,536

1. Affiliate business

(1) Basic information of significant associate of the Group is as follows:

Company name	Major places of business	Ratio of Shareholding			Measuring method
		June 30, 2025	December 31, 2024	Nature of relationship	
Chunghwa Chemical Synthesis & Biotech Co., Ltd.	Taiwan	28.05%	27.82%	Suppliers	Equity method
SINO-JAPAN CHEMICAL., CO., LTD	Taiwan	21.99%	21.99%	Financial investment	Equity method
Company name	Major places of business	Ratio of Shareholding		Nature of relationship	Measuring method
Company name	Major places of business	June 30, 2024			
Chunghwa Chemical Synthesis & Biotech Co., Ltd.	Taiwan	27.82%		Suppliers	Equity method
SINO-JAPAN CHEMICAL., CO., LTD	Taiwan	21.99%		Financial investment	Equity method

(2) Financial information of the Group's major associates is summarized as follows:

Balance Sheet

	Chunghwa Chemical Synthesis & Biotech Co., Ltd.		
	June 30, 2025	December 31, 2024	June 30, 2024
Current assets	\$ 1,295,166	\$ 1,441,225	\$ 1,633,254
Non-Current assets	3,297,496	3,321,513	3,361,214
Current liabilities	( 460,021)	( 425,288)	( 663,916)
Non-current liabilities	( 874,360)	( 980,510)	( 983,170)
Total net assets	<u>\$ 3,258,281</u>	<u>\$ 3,356,940</u>	<u>\$ 3,347,382</u>
Book value of the associate	<u>\$ 962,543</u>	<u>\$ 987,475</u>	<u>\$ 1,012,438</u>

	SINO-JAPAN CHEMICAL., CO., LTD		
	June 30, 2025	December 31, 2024	June 30, 2024
Current assets	\$ 2,124,603	\$ 2,463,482	\$ 2,289,974
Non-Current assets	621,080	607,666	513,261
Current liabilities	( 348,287)	( 519,015)	( 417,073)
Non-current liabilities	( 99,098)	( 101,740)	( 131,568)
Total net assets	<u>\$ 2,298,298</u>	<u>\$ 2,450,393</u>	<u>\$ 2,254,594</u>
Book value of the associate	<u>\$ 486,162</u>	<u>\$ 519,603</u>	<u>\$ 476,553</u>

Comprehensive income statement

	Chunghwa Chemical Synthesis & Biotech Co., Ltd.	
	April 1 to June 30, 2025	April 1 to June 30, 2024
Income	<u>\$ 344,039</u>	<u>\$ 461,158</u>
Current year profit of continuing business units	(\$ 67,332)	\$ 21,077
Other comprehensive income (post-tax profit or loss)	( 16,760)	( 5,414)
Current period other comprehensive income (Gross)	<u>(\$ 84,092)</u>	<u>\$ 15,663</u>

	Chunghwa Chemical Synthesis & Biotech Co., Ltd.	
	January 1 to June 30, 2025	January 1 to June 30, 2024
Income	\$ 536,991	\$ 712,870
Current year profit of continuing business units	(\$ 60,014)	\$ 61,632
Other comprehensive income (post- tax profit or loss)	( 5,384)	( 2,437)
Current period other comprehensive income (Gross)	(\$ 65,398)	\$ 59,195

	SINO-JAPAN CHEMICAL., CO., LTD	
	April 1 to June 30, 2025	April 1 to June 30, 2024
Income	\$ 653,512	\$ 879,473
Current year profit of continuing business units	\$ 45,561	\$ 127,044
Current period other comprehensive income (Gross)	\$ 45,561	\$ 127,044

	SINO-JAPAN CHEMICAL., CO., LTD	
	January 1 to June 30, 2025	January 1 to June 30, 2024
Income	\$ 1,270,844	\$ 1,545,535
Current year profit of continuing business units	\$ 96,792	\$ 171,351
Current period other comprehensive income (Gross)	\$ 96,792	\$ 171,351
Dividends received from affiliated subsidiaries	\$ 54,722	\$ 68,694

- (3) The share of the operating results of individual insignificant associates of the Group is summarized as follows:

	April 1 to June 30, 2025	April 1 to June 30, 2024
Net loss of current period	(\$ 2,818)	(\$ 1,551)
	January 1 to June 30, 2025	January 1 to June 30, 2024
Net loss of current period	(\$ 4,124)	(\$ 3,039)

(4) The shares of profit and/or loss at equity method over the associates as follows:

Name of affiliated enterprise	April 1 to June 30, 2025	April 1 to June 30, 2024
Chunghwa Chemical Synthesis & Biotech Co., Ltd.	(\$ 21,451)	\$ 2,825
SINO-JAPAN CHEMICAL., CO., LTD	10,017	27,932
PHERMPEP CO., LTD.	( 563)	( 1,517)
Wuxi Jirui Medical Technology Co., Ltd.	( 2,255)	( 34)
	<u>(\$ 14,252)</u>	<u>\$ 29,206</u>

Name of affiliated enterprise	January 1 to June 30, 2025	January 1 to June 30, 2024
Chunghwa Chemical Synthesis & Biotech Co., Ltd.	(\$ 24,478)	\$ 10,241
SINO-JAPAN CHEMICAL., CO., LTD	21,281	37,674
PHERMPEP CO., LTD.	( 1,867)	( 3,003)
Wuxi Jirui Medical Technology Co., Ltd.	( 2,257)	( 36)
	<u>(\$ 7,321)</u>	<u>\$ 44,876</u>

(5) The significant associate of the Group-CCSB is public offering and its fair values of June 30, 2025, December 31 and June 30, 2024 are, respectively, NTD 781,017, NTD 731,395 and NTD 1,132,691.

(6) The Group holds 28.05% equity of Chunghwa Chemical Synthesis Biotech Co., Ltd. (CCSB) and is the largest shareholder of CCSB. Considering the participation of other shareholders in the previous shareholders meeting of CCSB and the record of voting rights casted on major proposals, it indicates that the Group is incapable of leading relevant activities. Therefore, it has no control over CCSB, but a significant influence.

## 2. Joint venture

(1) The basic information of the important joint ventures is as follows:

1. The Company established a joint venture with MegaPro Biomedical Co., Ltd. and Suzhou Tianjian Yunkang Information Technology Co., Ltd. to develop new pharmaceuticals by holding 40% of total shares in the joint venture. The Company invested NTD 24,372 (US\$ 800,000) in April 2023. As the subsidiary, Suzhou Tianjian Yunkang Information Technology Co., Ltd. had not completed the relevant capital increase procedures, its shareholding ratio changed from 40% to 57.14%. In addition, on February 1, 2024, the Board of Directors resolved to cease the operations of Trium Therapeutics Co., Ltd. On May 24, 2024, all the joint venture parties resolved to dissolve Trium Therapeutics Co., Ltd., and on May 28, 2024, NTD 25,349 was recovered from the investment.

2. The Group holds more than 50% of the shares in Trium Therapeutics Co., Ltd. However, as decisions on the company's relevant activities are jointly decided by all joint venture parties as stated in the joint venture agreement, the Group has no ultimate control over it, so Trium Therapeutics Co., Ltd. is not listed as a consolidated entity.

(2) Financial information of the Group's major joint venture is summarized as follows:

Comprehensive income statement

	Trium Therapeutics Co., Ltd	
	April 1 to June 30, 2025	April 1 to May 24, 2024
Income	\$ -	\$ -
Current net (losses) from continuing operations	\$ -	\$ 87
Current period other comprehensive income (Gross)	\$ -	\$ 87
	January 1 to June 30, 2025	January 1 to May 24, 2024
Income	\$ -	\$ -
Current net (losses) from continuing operations	\$ -	\$ 7
Current period other comprehensive income (Gross)	\$ -	\$ 7

(3) The shares of profit and/or loss at equity method over the joint venture as follows:

Name of investee	April 1 to June 30, 2025	April 1 to May 24, 2024
Trium Therapeutics Co., Ltd	\$ -	\$ 50
Name of investee	January 1 to June 30, 2025	January 1 to May 24, 2024
Trium Therapeutics Co., Ltd	\$ -	\$ 4

(8) Property, plant, and equipment

	2025						
	Land	Buildings and structures	Machinery equipment	Transport equipment	Uncompleted construction and equipment pending inspection	Others	Total
January 1							
Cost	\$ 1,021,812	\$ 3,577,674	\$ 1,610,150	\$ 41,681	\$ 113,032	\$ 1,372,199	\$ 7,736,548
Accumulated depreciation	-	( 1,727,106)	( 988,606)	( 33,458)	-	( 910,063)	( 3,659,233)
	<u>\$ 1,021,812</u>	<u>\$ 1,850,568</u>	<u>\$ 621,544</u>	<u>\$ 8,223</u>	<u>\$ 113,032</u>	<u>\$ 462,136</u>	<u>\$ 4,077,315</u>
January 1	\$ 1,021,812	\$ 1,850,568	\$ 621,544	\$ 8,223	\$ 113,032	\$ 462,136	\$ 4,077,315
Additions	-	6,152	26,791	1,219	25,558	12,439	72,159
Transfer	-	2,186	36,538	20	( 52,767)	14,023	-
Disposition	-	-	-	( 87)	-	( 23)	( 110)
Depreciation expenses	-	( 52,223)	( 40,554)	( 1,421)	-	( 45,141)	( 139,339)
Net exchange differences	-	( 7,888)	( 7,214)	( 221)	( 889)	( 4,813)	( 21,025)
June 30	<u>\$ 1,021,812</u>	<u>\$ 1,798,795</u>	<u>\$ 637,105</u>	<u>\$ 7,733</u>	<u>\$ 84,934</u>	<u>\$ 438,621</u>	<u>\$ 3,989,000</u>
June 30							
Cost	\$ 1,021,812	\$ 3,574,146	\$ 1,640,346	\$ 41,137	\$ 84,934	\$ 1,372,623	\$ 7,734,998
Accumulated depreciation	-	( 1,775,351)	( 1,003,241)	( 33,404)	-	( 934,002)	( 3,745,998)
	<u>\$ 1,021,812</u>	<u>\$ 1,798,795</u>	<u>\$ 637,105</u>	<u>\$ 7,733</u>	<u>\$ 84,934</u>	<u>\$ 438,621</u>	<u>\$ 3,989,000</u>

		2024						
		Land	Buildings and structures	Machinery equipment	Transport equipment	Uncompleted construction and equipment pending inspection	Others	Total
January 1								
Cost		\$ 1,021,812	\$ 3,599,064	\$ 1,464,504	\$ 41,160	\$ 132,628	\$ 1,251,156	\$ 7,510,324
Accumulated depreciation		-	( 1,626,922)	( 907,944)	( 32,610)	-	( 822,710)	( 3,390,186)
		<u>\$ 1,021,812</u>	<u>\$ 1,972,142</u>	<u>\$ 556,560</u>	<u>\$ 8,550</u>	<u>\$ 132,628</u>	<u>\$ 428,446</u>	<u>\$ 4,120,138</u>
January 1		\$ 1,021,812	\$ 1,972,142	\$ 556,560	\$ 8,550	\$ 132,628	\$ 428,446	\$ 4,120,138
Additions		-	4,413	25,209	610	78,536	35,161	143,929
Transfer		-	2,837	3,001	-	( 11,001)	5,163	-
Disposition		-	-	( 39)	( 580)	-	( 124)	( 743)
Depreciation expenses		-	( 53,810)	( 48,834)	( 1,357)	-	( 46,150)	( 150,151)
Net exchange differences		-	2,228	2,038	67	311	1,600	6,244
June 30		<u>\$ 1,021,812</u>	<u>\$ 1,927,810</u>	<u>\$ 537,935</u>	<u>\$ 7,290</u>	<u>\$ 200,474</u>	<u>\$ 424,096</u>	<u>\$ 4,119,417</u>
June 30								
Cost		\$ 1,021,812	\$ 3,609,281	\$ 1,486,041	\$ 40,345	\$ 200,474	\$ 1,294,829	\$ 7,652,782
Accumulated depreciation		-	( 1,681,471)	( 948,106)	( 33,055)	-	( 870,733)	( 3,533,365)
		<u>\$ 1,021,812</u>	<u>\$ 1,927,810</u>	<u>\$ 537,935</u>	<u>\$ 7,290</u>	<u>\$ 200,474</u>	<u>\$ 424,096</u>	<u>\$ 4,119,417</u>

- Notes: 1. Please refer to Note 8 for the information on the property, plant, and equipment provided as collateral.
2. When the Group obtains government subsidies for property, plant and equipment, it is debited to the carrying amount and recognized in profit or loss through a decrease in depreciation expenses over the useful life of the asset.
3. The Group rented the land of No. 23, Xiangyang Rd., Taipei City from Jen-Chi Relief Institution, the lease term is from January 1, 2015 to December 31, 2024 with the rental of NTD 259 to NTD 322 paid by the month. The Group re-signed the lease contract in 2024, with a lease period from January 1, 2025 to December 31, 2029, and the rent of NTD 322 is paid on a monthly basis. According to contractual requirement, if the contract is not renewed at expiration, the construction on the lease land shall unconditionally be torn down and the land should be returned. As of June 30 2025, the remaining balance of depreciation of the construction amounted to NTD 50,464.

(9) Lease transaction - lessee

1. Underlying assets leased by the Group include land lots, machine and equipment and business vehicles with lease term ranged one to fifty years. Lease agreements were negotiated individually with various terms and conditions. There are specific no restrictions specified, except that the leased assets cannot be used as loan guarantee.
2. Carrying amount and recognized amortization for right-of-use assets are as follows:

	June 30, 2025	December 31, 2024	June 30, 2024
	Book value	Book value	Book value
Land	\$ 47,600	\$ 50,969	\$ 35,146
Buildings	285,889	276,559	297,893
Machinery equipment	37,700	43,341	45,060
Delivery facilities (business vehicles)	7,784	4,430	5,620
	<u>\$ 378,973</u>	<u>\$ 375,299</u>	<u>\$ 383,719</u>

	April 1 to June 30, 2025	April 1 to June 30, 2024
	Depreciation expenses	Depreciation expenses
Land	\$ 967	\$ 950
Buildings	10,857	10,334
Machinery equipment	982	1,028
Delivery facilities (business vehicles)	1,049	704
	<u>\$ 13,855</u>	<u>\$ 13,016</u>

	January 1 to June 30, 2025	January 1 to June 30, 2024
	Depreciation expenses	Depreciation expenses
Land	\$ 1,940	\$ 1,897
Buildings	21,470	20,000
Machinery equipment	2,021	2,034
Delivery facilities (business vehicles)	2,099	1,550
	<u>\$ 27,530</u>	<u>\$ 25,481</u>

3. The Group's right-of-use assets for the six months ended June 30, 2025 and 2024 increased by NTD 46,329 and NTD 23,450 respectively.
4. Profit and loss items relating to lease contracts:

	April 1 to June 30, 2025	April 1 to June 30, 2024
<u>Profit and loss items with current impacts</u>		
Interest expense on the lease liability	\$ 1,801	\$ 1,700
Low-value leases expense	622	861
Short-term lease expense	4,648	4,247

	January 1 to June 30, 2025	January 1 to June 30, 2024
<u>Profit and loss items with current impacts</u>		
Interest expense on the lease liability	\$ 3,512	\$ 3,368
Low-value leases expense	1,101	1,343
Short-term lease expense	8,513	8,226

5. The Group's total lease cash outflows for the six months ended June 30, 2025 and 2024 were NTD 37,540 and NTD 34,856, respectively.

6. Options to extend lease:

- (1) Options to extend lease term are included in land leases for office buildings, which have helped increase operation agility for the Group.
- (2) Upon determining lease term, the Group has factored in all facts and condition that would produce future economy incentives. Lease term will be reassessed in the case of significant events when the decision of whether to exercise the extension option or not exercise the termination option is affected.
- (3) Given the assessment of exercising an option to extend the lease, the right-of-use assets and lease liabilities increased by NTD 16,492, NTD 16,492 and NTD 23,470 on June 30, 2025, December 31, and June 30, 2024, respectively.

7. Sub-subsidiary, Suzhou Chung-Hua Chemical & Pharmaceutical has received a subsidy of NTD 110,460 (or RMB 22,950 thousand) from the local government industrial funding, which was to reduce the cost of the rights to use land (recorded as long-term prepaid rent). The subsidy was then transferred to "right-of-use asset" in 2019 and will be recognized as depreciation expenses under profit and loss throughout the lease term.

8. As the Group has leased some buildings and is contractually obligated to dismantle, remove, or restore the location(s), the present value of the costs expected to be incurred in dismantling, removing, or restoring the location(s) was recognized in decommissioning liabilities as of June 30, 2025. The decommissioning liabilities recognized by the Group totaled NTD 4,637 and NTD 4,571 (recognized in other non-current liabilities), and the amortized interest expense for the three months and six months ended June 30, 2025 and 2024 were NTD 16, NTD 17, NTD 33 and NTD 33, respectively.

(10) Other non-current assets

	June 30, 2025	December 31, 2024	June 30, 2024
Prepayments for equipment	\$ 21,097	\$ 34,071	\$ 60,644
Refundable deposits	63,556	55,993	77,630
Long-term pre-paid payment	36,856	36,856	36,856
Long-term prepayments	12,893	9,147	5,523
Prepaid intangible assets	101,409	99,210	78,685
Defined benefit assets	2,234	1,483	-
Other non-current assets- Other	10,705	26,104	35,808
Less: accumulated impairment	( 30,747)	( 30,747)	( 30,747)
	<u>\$ 218,003</u>	<u>\$ 232,117</u>	<u>\$ 264,399</u>

The long-term prepaid goods and accumulated impairment are the result of subsidiary Chunghwa Yuming signing the distribution agreement for the new medicine with the vendor, Regulon, in July 2011 with the total amount of EUR 1,800,000. The Company had paid NTD 36,856 (EUR 900,000) for the new medicine. However, after evaluation in 2015, Chunghwa Yuming realized that the development of such new medicine was not as expected; therefore, a recognition of an impairment loss of NTD 30,747 was recorded.

(11) Short-term borrowings

	June 30, 2025	December 31, 2024	June 30, 2024
Financial institution loan			
Secured loans	\$ 1,348,751	\$ 681,000	\$ 670,013
Credit loan	530,800	700,789	584,700
	<u>\$ 1,879,551</u>	<u>\$ 1,381,789</u>	<u>\$ 1,254,713</u>
Interest rate collars	1.75%~2.545%	1.75%~2.545%	1.75%~2.545%

By June 30, 2025, December 31 and June 30, 2024, besides the short-term loan amount as stated in Note 8, the Group has issued cashier's checks, respectively, with NTD 1,737,840, NTD 1,820,000 and NTD 1,589,720 as collateral.

(12) Short-term notes payable

	June 30, 2025	December 31, 2024	June 30, 2024
Commercial papers	\$ 377,000	\$ 89,000	\$ 666,000
Less: Discount of short-term notes and bills payable	-	( 8)	-
	<u>\$ 377,000</u>	<u>\$ 88,992</u>	<u>\$ 666,000</u>
Interest rate collars	1.50%~1.87%	1.46%~1.72%	1.45%~2.03%

The short-term bill is guaranteed by the bills finance company and financial instrument which is issued for short-term capital use, by June 30, 2025, December 31 and June 30, 2024, the cashier's checks have been issued, respectively, with NTD 780,000, NTD 821,000 and NTD 821,000 as collateral for short-term bill receivable.

(13) Other payables

	June 30, 2025	December 31, 2024	June 30, 2024
Salary and bonus payables	\$ 274,299	\$ 360,451	\$ 276,689
Remuneration to employees and directors payable	99,000	65,000	55,000
Accrued expenses	191,681	216,097	183,468
Dividends payable	148,927	-	149,041
Commission payable	53,022	49,290	46,909
Construction equipment amount payable	20,899	38,688	27,672
Other payables	24,124	27,227	20,178
	<u>\$ 811,952</u>	<u>\$ 756,753</u>	<u>\$ 758,957</u>

(14) Long-term borrowings

	June 30, 2025	December 31, 2024	June 30, 2024
Financial institution loan			
Secured loans	\$ 282,900	\$ 395,500	\$ 295,500
Credit loan	140,000	920,000	527,000
	422,900	1,315,500	822,500
Less: long-term borrowing due within 12 months	( 25,200)	( 25,200)	( 12,600)
	<u>\$ 397,700</u>	<u>\$ 1,290,300</u>	<u>\$ 809,900</u>
Interest rate collars	1.99%~2.23%	1.99%~2.01%	1.80%~2.01%

1. Repayment period for credit loans and secured loans from 2026 to 2029.

2. The detail for the unused loan amount of The Group is as follows:

	June 30, 2025	December 31, 2024	June 30, 2024
Floating annual rate			
Maturing in one year or less	\$ 1,957,720	\$ 2,387,251	\$ 1,724,339
Mature beyond one year	1,123,000	600,000	1,343,000
	<u>\$ 3,080,720</u>	<u>\$ 2,987,251</u>	<u>\$ 3,067,339</u>

By June 30, 2025, December 31 and June 30, 2024, the cashier's checks have been issued, respectively, with NTD 1,070,000, NTD 1,310,000 and NTD 1,610,000 as collateral for the long-term loan amounts as stated.

3. Please refer to Note 8 for description of collateral.

(15) Pension

1. (1) The Company and its domestic subsidiaries have a defined benefit pension plan in accordance with the "Labor Standards Act", covering all regular employees' service years prior to the enforcement of the Labor Pension Act on July 1, 2005 and service years thereafter of employees who chose to continue to be subject to the pension mechanism under the Law. When an employee meets the requirements of retirement, the payment of pension is based on service years and the average salary of the six months prior to retirement, with services within 15 years accumulating 2 basis points per year, and service years beyond 15 years accumulating 1 basis point per year up to a maximum of 45 basis points. The company and subsidiary companies provisions 2~6% of total monthly salary to the pension fund in the name of the Pension Supervisory Committee at the Bank of Taiwan. In addition, the Company and subsidiary have the labor pension reserve account balance referred to in the preceding paragraph estimated at the end of each fiscal year. If the account balance is insufficient to pay pension benefit to the employees who qualify for retirement within next year for the pension benefit calculated in the preceding paragraph, the Company and subsidiary will have the spread amount appropriated in a lump sum before the end of March next year.
  - (2) For the three months and six months ended June 30, 2025 and 2024, the net pension cost recorded by the company according to the above mentioned pension plans are NTD 287, NTD 554, NTD 611 and NTD 1,109 respectively.
  - (3) The Group has appropriated NTD 10,840 to the pension plan in 2025.
2. (1) Since July 1, 2005, the company and domestic subsidiaries have established definitive provision pension scheme for employees with Taiwan nationality in accordance with the "Labor Pension Act". The Company and its domestic subsidiaries have established a defined contribution pension plan (the "New Plan") under the "Labor Pension Act" covering all regular employees. Under the New Plan, the Group contributes monthly an amount based on 6% of the employees' monthly salaries and wages to an employee's individual pension account at the Bureau of Labor Insurance. The payment of pension benefits is based on an employee's individual pension fund account and the cumulative profit in such account, and employees can choose to receive such pension benefits monthly or in one lump sum.
  - (2) In terms of the pension insurance system of the Sub-subsidiary, SCCPC regulated by the government of the People's Republic of China, pension insurance premiums based on a certain percentage of the total salary of local employees are appropriated every month. The ratio are 16% for the three months and six months ended June 30, 2025 and 2024. The pension of each employee is arranged by the government. The Group has no further obligations other than appropriating the pension each month.
  - (3) For the three months and six months ended June 30, 2025 and 2024, the net pension cost recorded by the company according to the above mentioned pension plans are NTD 25,455, NTD 24,445, NTD 51,592 and NTD 48,811 respectively.

(16) Capital stock

1. On September 2, 2024, the Company acquired 100% of the equity of CCPC by 0.5 share of the Company for every 1 share of CCPC. As of June 30, 2025, the Company's authorized capital was NTD 5,000,000, and the actual number of common shares issued was 149,041 thousand, with a paid-in capital of NTD 1,490,405, with a par value of \$10 per share.
2. The beginning and ending outstanding shares for the financial statements for the comparative period of the Company for the six months ended June 30, 2025 and 2024 were as follows: (Unit: thousand shares)

	<u>2025</u>	<u>2024</u>
January 1	148,514	297,253
Repurchase of treasury stock	( 2,489)	-
June 30	<u>146,025</u>	<u>297,253</u>

3. As of June 30, 2025, December 31 and June 30, 2024, due to long-term investment, Tairung Enterprise Co., Ltd. held 414 thousand shares, 414 thousand shares and 828 thousand shares of the Company and CCPC (prior to the share swap) respectively, with an average carrying amount of NTD 67.78, NTD 67.78 per share and NTD 33.89 per share, respectively. The fair value per share was NTD 36.2, NTD 37.4 and NTD 22.8, respectively.
4. As of June 30, 2025, December 31 and June 30, 2024, the associates of the Company held 21,027 thousand shares, 21,027 thousand shares and 42,053 thousand shares of the Company and CCPC (prior to the share swap), respectively.
5. The Company's Board of Directors resolved to buy back treasury shares and transfer shares to employees on April 9, 2025 and December 26, 2024, respectively. The buyback period expired on June 9, 2025, and February 26, 2025. During the second quarter of 2025, 2,489 thousand shares were repurchased for a total of NTD 93,628 thousand. The Company's recovery of treasury stocks is as follows:

		<u>June 30, 2025</u>	
<u>Name of holding company</u>	<u>Reasons for recovery</u>	<u>Number of shares (thousand shares)</u>	<u>Book value</u>
The Company	for transfer of shares to employees	2,602	\$ 97,878

  

		<u>December 31, 2024</u>	
<u>Name of holding company</u>	<u>Reasons for recovery</u>	<u>Number of shares (thousand shares)</u>	<u>Book value</u>
The Company	for transfer of shares to employees	113	\$ 4,250

- (1) According to the Securities and Exchange Act, the percentage of shares repurchased by the Company shall not exceed 10% of the total number of issued shares, and the total amount of the repurchase shall not exceed the sum of retained earnings plus the premium of issued shares and the realized capital reserve.
  - (2) The treasury stock held by the Company shall not be pledged and shall not be entitled to the rights of shareholders before transfer in accordance with the Securities and Exchange Act.
  - (3) According to the Securities and Exchange Act, the shares repurchased for transfer to employees should be transferred within five years from the date of repurchase. If the shares are not transferred after the expiration date, they should be deemed as unissued shares of the Company and should be canceled for change of registration.
6. On March 6, 2025, the Company's Board of Directors passed the issuance of common shares or domestic convertible bonds (including secured or unsecured convertible bonds) through private placement. The actual number of issued or convertible shares shall be submitted to the shareholders' meeting, and the board of directors are authorized to issue common shares of no more than 20% of the total number of issued shares (i.e. no more than 29,808,108 shares), depending on the capital market conditions via private placement. This private placement was approved by the shareholders' meeting on May 27, 2025.

(17) Capital surplus

		2025			
		Issuance premium	Treasury stock trade	Difference between the actual acquisition or disposal of equity interest in a subsidiary and its book value	Others Changes in the ownership equity on a subsidiary
January 1		\$ 5,901,560	\$ 68,087	\$ 112	\$ 1,844
Distribution of cash from capital reserve	( 89,356)		-	-	-
June 30		<u>\$ 5,812,204</u>	<u>\$ 68,087</u>	<u>\$ 112</u>	<u>\$ 1,844</u>
		2024			
		Issuance premium	Treasury stock trade	Difference between the actual acquisition or disposal of equity interest in a subsidiary and its book value	Others Changes in the ownership equity on a subsidiary
January 1 (i.e. June 30)		<u>\$ 578,416</u>	<u>\$ 67,842</u>	<u>-</u>	<u>\$ 1,844</u>

1. According to the IFRS Q&A set and Letter (100) Ji-Mi-Zi No. 390 issued by the Accounting Research and Development Foundation dated October 26, 2018, the share exchange transaction between the CCPC on September 2, 2024 was deemed a reorganization under joint control. The Company is a continuation of the CCPC. The Company has reclassified the equity items related to the reorganization of assets and liabilities to the original amount, and the balance of the equity items exceeding the Company's newly issued capital stock and the aforementioned equity items to be deferred are adjusted to increase capital surplus.
2. According to the Company Act, capital reserves from premium income for issuing shares over face values and gift income, not only can offset losses, it can also issue new shares or cash according to the original shareholding when there is no accumulated losses in the company. According to the Securities Transactions Act and its related rules, where capital reserve is applied to supplement capital as above, the total amount cannot exceed 10% of the paid up capital. When the retained earnings of a company is not enough to offset capital losses, the capital reserves cannot be applied.

(18) Retained earnings

1. According to the Articles of Incorporation of the Company, the dividend policy is planned with consideration of the future capital requirements and long-term financial arrangements, as well as to meet the cash inflow requirements of the shareholders. If there are any earnings reported in the annual report, taxes should be paid first, followed by offsetting any previous annual losses. Next, 10% should be allocated as a legal reserve and special reserve in accordance with regulations. If any earnings remain, they will be accumulated with the undistributed earnings from the previous year to determine the profit available for distribution. This amount will be reserved at the discretion of management, and bonuses will be allocated to shareholders, with cash dividends comprising no less than 50% of the shareholder bonus. If the cash dividend is less than NTD 0.1, a stock dividend will be issued instead.
2. Legal earnings reserves can only be applied to offset company losses or issue new shares or cash according to the original shareholding ratio, and nothing else. When it is applied to new share or cash issues, the reserve shall be exceeding 25% of the paid-up capital.
3. (1) In accordance with the regulations, the Company shall set aside special reserve from the debit balance of other equity items at the balance sheet date before distributing earnings. When debit balance on other equity items is reversed subsequently, the reversed amount could be included in the distributable earnings.  
(2) As stated in Note 6(17), the Company is a continuation of CCPC. When it first adopted IFRSs, the Financial Supervisory Commission (FSC) issued Jin-Guan-Zheng-FA-Zi No. 1010012865. On April 6, 2012, which the Company adopts hereafter to implement, the disposal or reclassification of relevant assets is subject to a reversal based on the proportion of the special earned surplus as initially recognized. If the previously stated relevant assets are investment real properties, reversal with disposal or reclassification should be applied for those classified as land. For those assets other than land, the reversal should occur gradually while they are in use.
4. On May 27, 2025, the Company's shareholders meetings' resolved to distribute cash of NTD 0.6 per share from capital surplus, totaling NTD 89,356.
5. Upon the resolution made by the shareholders on May 27, 2025 and May 28, 2024, the disposition of earnings of the Company for 2024 and 2023 are as follows.

	2024		2023	
	Amount	Dividends per share (\$)	Amount	Dividends per share (\$)
Legal reserve	\$ 11,362	-	\$ 34,383	-
Special reserve	33,809	-	-	-
Cash dividends	59,571	0.4	149,041	0.5
	<u>\$ 104,742</u>		<u>\$ 183,424</u>	

The relevant information about the disposition of earnings as above stated which decided by the shareholders can be inquired on the “Market observation post system” of Taiwan Stock Exchange Corporation.

(19) Other equity

	2025		
	Unrealized loss of profit valuation	Foreign-currency translations	Total
January 1	(\$ 137,597)	(\$ 85,170)	(\$ 222,767)
Evaluation adjustment:			
- Group	( 5,470)	-	( 5,470)
- Valuation adjustment changes to retained earnings	61,981	-	61,981
Foreign currency translation differences:			
- Group	-	( 101,955)	( 101,955)
- Tax of the group	-	20,391	20,391
- Affiliated enterprises	-	( 453)	( 453)
June 30	<u>(\$ 81,086)</u>	<u>(\$ 167,187)</u>	<u>(\$ 248,273)</u>

	2024		
	Unrealized loss of profit valuation	Foreign-currency translations	Total
January 1	(\$ 30,507)	(\$ 116,566)	(\$ 147,073)
Evaluation adjustment:			
- Group	( 91,713)	-	( 91,713)
- Valuation adjustment changes to retained earnings	33,613	-	33,613
Foreign currency translation differences:			
- Group	-	30,890	30,890
- Tax of the group	-	( 6,178)	( 6,178)
- Affiliated enterprises	-	45	45
June 30	<u>(\$ 88,607)</u>	<u>(\$ 91,809)</u>	<u>(\$ 180,416)</u>

(20) Operating revenues

	<u>April 1 to June 30, 2025</u>	<u>April 1 to June 30, 2024</u>
Revenue from sales contract	\$ 2,063,564	\$ 2,177,470
Revenue from labor service contract	<u>43,472</u>	<u>38,252</u>
	<u>\$ 2,107,036</u>	<u>\$ 2,215,722</u>
	<u>January 1 to June 30, 2025</u>	<u>January 1 to June 30, 2024</u>
Revenue from sales contract	\$ 4,279,635	\$ 4,425,157
Revenue from labor service contract	<u>83,029</u>	<u>74,591</u>
	<u>\$ 4,362,664</u>	<u>\$ 4,499,748</u>

1. Subdivision of the revenue from contracts with customers

The Group generates revenue by transferring products and labor services to customers either at a point in time or over time. Revenue details are listed as follows:

<u>April 1 to June 30, 2025</u>	<u>Taiwan</u>	<u>China</u>	<u>Other regions</u>	<u>Total</u>
Sales contract	\$ 1,599,771	\$ 350,589	\$ 113,204	\$ 2,063,564
Labor service contract	<u>43,240</u>	<u>232</u>	<u>-</u>	<u>43,472</u>
	<u>\$ 1,643,011</u>	<u>\$ 350,821</u>	<u>\$ 113,204</u>	<u>\$ 2,107,036</u>
<u>April 1 to June 30, 2024</u>	<u>Taiwan</u>	<u>China</u>	<u>Other regions</u>	<u>Total</u>
Sales contract	\$ 1,612,458	\$ 486,399	\$ 78,613	\$ 2,177,470
Labor service contract	<u>38,252</u>	<u>-</u>	<u>-</u>	<u>38,252</u>
	<u>\$ 1,650,710</u>	<u>\$ 486,399</u>	<u>\$ 78,613</u>	<u>\$ 2,215,722</u>
<u>January 1 to June 30, 2025</u>	<u>Taiwan</u>	<u>China</u>	<u>Other regions</u>	<u>Total</u>
Sales contract	\$ 3,238,294	\$ 836,507	\$ 204,834	\$ 4,279,635
Labor service contract	<u>82,797</u>	<u>232</u>	<u>-</u>	<u>83,029</u>
	<u>\$ 3,321,091</u>	<u>\$ 836,739</u>	<u>\$ 204,834</u>	<u>\$ 4,362,664</u>

January 1 to June 30, 2024	Taiwan	China	Other regions	Total
Sales contract	\$ 3,147,746	\$ 1,095,899	\$ 181,512	\$ 4,425,157
Labor service contract	74,591	-	-	74,591
	<u>\$ 3,222,337</u>	<u>\$ 1,095,899</u>	<u>\$ 181,512</u>	<u>\$ 4,499,748</u>

2. Contractual liability

The contractual liability relating to the contract with a customer which The Group recognizes is as follows:

	June 30, 2025	December 31, 2024	June 30, 2024
Contractual liability- Sales contract of medicine	<u>\$ 32,409</u>	<u>\$ 31,026</u>	<u>\$ 19,757</u>

3. Current income recognized from beginning lease liability for the three months and six months ended June 30, 2025 and 2024 were NTD 988, NTD 7,125, NTD 12,563 and NTD 39,707, respectively.

4. The refund liability which The Group recognized for some goods with right of return is as follows:

	January 1 to June 30, 2025	January 1 to June 30, 2024
January 1	\$ 94,638	\$ 81,085
Increase of the current period	2,211	34,492
Used in the current period	( 23,431)	( 19,455)
June 30	<u>\$ 73,418</u>	<u>\$ 96,122</u>

(21) Interest income

	April 1 to June 30, 2025	April 1 to June 30, 2024
Interest from bank deposits	\$ 918	\$ 1,035
The interest revenue of financial assets at amortized cost	660	691
Other interest incomes	1,303	1,215
	<u>\$ 2,881</u>	<u>\$ 2,941</u>

	January 1 to June 30, 2025	January 1 to June 30, 2024
Interest from bank deposits	\$ 983	\$ 1,077
The interest revenue of financial assets at amortized cost	1,359	1,368
Other interest incomes	2,856	2,579
	<u>\$ 5,198</u>	<u>\$ 5,024</u>

(22) Other income

	<u>April 1 to June 30, 2025</u>	<u>April 1 to June 30, 2024</u>
Rent revenue	\$ 1,570	\$ 769
Dividend income	2,280	-
Grant income	2,602	2,538
Other Revenue- other	3,150	4,684
	<u>\$ 9,602</u>	<u>\$ 7,991</u>

  

	<u>January 1 to June 30, 2025</u>	<u>January 1 to June 30, 2024</u>
Rent revenue	\$ 3,612	\$ 1,929
Dividend income	2,280	-
Grant income	4,593	6,824
Other Revenue- other	4,288	9,105
	<u>\$ 14,773</u>	<u>\$ 17,858</u>

(23) Other profits and losses

	<u>April 1 to June 30, 2025</u>	<u>April 1 to June 30, 2024</u>
Gain in disposal of real estate, plant buildings, equipment & facilities	\$ 549	\$ 64
Net foreign exchange loss	( 5,136)	( 2,046)
Gain in financial assets at fair value through profit and loss	-	380
Depreciation of investment property	( 807)	( 479)
Others	533	-
	<u>(\$ 4,861)</u>	<u>(\$ 2,081)</u>

  

	<u>January 1 to June 30, 2025</u>	<u>January 1 to June 30, 2024</u>
Gain in disposal of real estate, plant buildings, equipment & facilities	\$ 571	\$ 27
Net foreign exchange loss	( 3,354)	( 4,471)
Gain in financial assets at fair value through profit and loss	-	890
Depreciation of investment property	( 1,640)	( 948)
Others	533	-
	<u>(\$ 3,890)</u>	<u>(\$ 4,502)</u>

(24) Employees' welfare and depreciation, amortization expenses

Functionality Characteristics	April 1 to June 30, 2025		
	Allocated as operating cost	Employee expenses	Total
Employee benefits expenses			
Salaries and wages	\$ 158,772	\$ 280,577	\$ 439,349
Labor insurance and national health insurance	17,006	21,837	38,843
Pension expenses	9,968	15,774	25,742
Other employee benefits expenses	10,926	16,955	27,881
Depreciation expenses	55,530	28,239	83,769
Amortization expenses	209	2,390	2,599

Functionality Characteristics	April 1 to June 30, 2024		
	Allocated as operating cost	Employee expenses	Total
Employee benefits expenses			
Salaries and wages	\$ 157,833	\$ 270,695	\$ 428,528
Labor insurance and national health insurance	15,674	20,424	36,098
Pension expenses	9,799	15,200	24,999
Other employee benefits expenses	12,849	18,110	30,959
Depreciation expenses	61,050	27,911	88,961
Amortization expenses	190	2,853	3,043

Functionality Characteristics	January 1 to June 30, 2025		
	Allocated as operating cost	Employee expenses	Total
Employee benefits expenses			
Salaries and wages	\$ 318,646	\$ 567,156	\$ 885,802
Labor insurance and national health insurance	34,620	46,051	80,671
Pension expenses	20,314	31,889	52,203
Other employee benefits expenses	22,521	31,611	54,132
Depreciation expenses	109,759	57,110	166,869
Amortization expenses	277	5,046	5,323

Functionality Characteristics	January 1 to June 30, 2024		
	Allocated as operating cost	Employee expenses	Total
Employee benefits expenses			
Salaries and wages	\$ 314,012	\$ 542,661	\$ 856,673
Labor insurance and national health insurance	32,033	42,807	74,840
Pension expenses	19,609	30,311	49,920
Other employee benefits expenses	25,758	33,627	59,385
Depreciation expenses	120,409	55,223	175,632
Amortization expenses	380	5,705	6,085

1. According to the Articles of Incorporation as amended by the Company's shareholders' meeting on May 27, 2025, if a balance remains after deducting accumulated losses from the current year's profit, 1% to 15% of the balance shall be appropriated as remuneration to employees, and no more than 3% as remuneration to directors. Of the employee remuneration, no less than 10% shall be allocated to entry-level employees.
2. (1) The estimated amount of employee remuneration for the three months and the six months ended June 30, 2025 was NTD 3,900 and NTD 7,800, respectively; the estimated amount of director remuneration was NTD 1,750 and NTD 3,500, respectively. The aforementioned amount was recorded in the account of salary expense.
  - (2) For the three months and six months ended June 30, 2024, CCPC's estimated amount of remuneration to employees were NTD 11,250 and NTD 22,500, respectively, and the estimated amount of remuneration to directors were NTD 1,250 and NTD 2,500, respectively. The aforementioned amounts were recognized as salary expenses.
  - (3) The estimated recognition for the six months ended June 30, 2025 is based on the profitability of the year, of which 3.21% for employee bonus and 1.44% for the bonus of the members of the board. The above stated employee bonus is distributed in cash.
  - (4) The estimated amount of remuneration to employees from September 2, 2024 (the date of establishment) to December 31, 2024 was NTD 5,328, and the estimated amount of remuneration to directors was NTD 2,417, as resolved by the Board of Directors was same as the amount reported in the 2024 financial statements. The remuneration to employees and directors/supervisors from September 2, 2024 to December 31, 2024 had not been paid out.
3. Information on the employee and remuneration for directors as approved by the board of directors can be found on the Market Observation Post System.

(25) Financial costs

	<u>April 1 to June 30,</u> <u>2025</u>	<u>April 1 to June 30,</u> <u>2024</u>
Interest expenses:		
Bank loan	\$ 13,530	\$ 13,588
Interest expense on the lease liability	1,801	1,700
Interest expense on decommissioning liabilities	<u>16</u>	<u>17</u>
	<u>\$ 15,347</u>	<u>\$ 15,305</u>
	<u>January 1 to June 30,</u> <u>2025</u>	<u>January 1 to June 30,</u> <u>2024</u>
Interest expenses:		
Bank loan	\$ 27,627	\$ 28,417
Interest expense on the lease liability	3,512	3,368
Interest expense on decommissioning liabilities	<u>33</u>	<u>33</u>
	<u>\$ 31,172</u>	<u>\$ 31,818</u>

(26) Income tax

1. Income tax expense

(1) Components of income tax expense:

	<u>April 1 to June 30, 2025</u>	<u>April 1 to June 30, 2024</u>
Current income tax:		
Current income tax	\$ 32,852	\$ 18,390
Additional levy on undistributed earnings	3,834	6,522
Underestimated (overestimated) income tax in prior periods	<u>3,139</u>	<u>(4,139)</u>
Total Current income tax	<u>39,825</u>	<u>20,773</u>
Deferred income tax:		
Origin and reversal of temporary differences	<u>(3,155)</u>	<u>(6,077)</u>
Total deferred income tax	<u>(3,155)</u>	<u>(6,077)</u>
Income tax expenses	<u>\$ 36,670</u>	<u>\$ 14,696</u>

January 1 to June 30, 2025      January 1 to June 30, 2024

Current income tax:			
Current income tax	\$	64,570	\$ 34,430
Additional levy on undistributed earnings		3,834	6,522
Underestimated (overestimated) income tax in prior periods		6,810	(4,099)
Total Current income tax		<u>75,214</u>	<u>36,853</u>
Deferred income tax:			
Origin and reversal of temporary differences	(	9,130)	3,182
Total deferred income tax	(	9,130)	3,182
Income tax expenses	\$	<u>66,084</u>	\$ <u>40,035</u>

(2) Income tax amounts relating to other comprehensive profit and loss:

	<u>April 1 to June 30, 2025</u>	<u>April 1 to June 30, 2024</u>
Exchange differences in overseas operating institutions	<u>(\$ 25,589)</u>	<u>\$ 1,897</u>
	<u>January 1 to June 30, 2025</u>	<u>January 1 to June 30, 2024</u>
Exchange differences in overseas operating institutions	<u>(\$ 20,391)</u>	<u>\$ 6,178</u>

2. The CCPC income tax return up to 2022 had been examined by the tax authorities. Filing from all other domestic subsidiaries within the Group had been examined by the tax authorities, up to 2023.

(27) Earnings per share

	April 1 to June 30, 2025		
	After-tax amount	Weighted average outstanding shares (thousand shares)	Earnings per share (NTD)
<u>Basic earnings per share</u>			
Net income attributable to the parent company's common stock shareholders	\$ 47,334	125,844	\$ 0.38
<u>Diluted earnings per share</u>			
Net income attributable to the parent company's common stock shareholders	\$ 47,334	125,844	
The impact of potential diluting common stock: remuneration to employees	-	215	
Net income attributable to the parent company and impact of potential common stock	\$ 47,334	126,059	\$ 0.38
	April 1 to June 30, 2024		
	After-tax amount	Weighted average outstanding shares (thousand shares)	Earnings per share (NTD)
<u>Basic earnings per share</u>			
Net income attributable to the parent company's common stock shareholders	\$ 80,253	148,627	\$ 0.54
<u>Diluted earnings per share</u>			
Net income attributable to the parent company's common stock shareholders	\$ 80,253	148,627	
The impact of potential diluting common stock: remuneration to employees	-	493	
Net income attributable to the parent company and impact of potential common stock	\$ 80,253	149,120	\$ 0.54
	January 1 to June 30, 2025		

	After-tax amount	Weighted average outstanding shares (thousand shares)	Earnings per share (NTD)
<u>Basic earnings per share</u>			
Net income attributable to the parent company's common stock shareholders	\$ 165,328	126,393	\$ 1.31
<u>Diluted earnings per share</u>			
Net income attributable to the parent company's common stock shareholders	\$ 165,328	126,393	
The impact of potential diluting common stock: remuneration to employees	-	265	
Net income attributable to the parent company and impact of potential common stock	\$ 165,328	126,658	\$ 1.31
January 1 to June 30, 2024			
	After-tax amount	Weighted average outstanding shares (thousand shares)	Earnings per share (NTD)
<u>Basic earnings per share</u>			
Net income attributable to the parent company's common stock shareholders	\$ 186,086	148,627	\$ 1.25
<u>Diluted earnings per share</u>			
Net income attributable to the parent company's common stock shareholders	\$ 186,086	148,627	
The impact of potential diluting common stock: remuneration to employees	-	704	
Net income attributable to the parent company and impact of potential common stock	\$ 186,086	149,331	\$ 1.25

The Company exchanged shares with CCPC according to the share swap agreement. As it is deemed the reorganization under joint control, the Company retroactively adjusted the weighted average number of outstanding shares based on the share swap ratio agreed upon in the share swap agreement when calculating the earnings per share during the comparative period.

(28) Supplementary information about the cash flows

1. Investing activities partially funded with cash:

	January 1 to June 30, 2025	January 1 to June 30, 2024
Purchase of property, plant, and equipment	\$ 72,159	\$ 143,929
Less: Initial prepayments for business facilities	( 34,071)	( 36,702)
Add: Ending prepayment for business facilities	21,097	60,644
Add: Construction and equipment payable at the beginning of the period	38,688	49,842
Less: Construction and equipment payable at the Ending of the period	( 20,899)	( 27,672)
Add: Long-term payables for construction and prepayments for business at the beginning of the period (recognized in other non-current liabilities)	8,299	8,787
Less: Long-term payables for construction and prepayments for business at the end of the period (recognized in other non-current liabilities)	( 8,299)	( 8,299)
Cash Paid for the Period	<u>\$ 76,974</u>	<u>\$ 190,529</u>

2. Financing activities that did not affect cash flow

	January 1 to June 30, 2025	January 1 to June 30, 2024
Cash dividends payable	<u>\$ 148,927</u>	<u>\$ 149,041</u>

(29) Changes in liability from financial activities.

	Shot-term borrowings	Short-term notes payable	Long-term borrowings	Lease liabilities	Deposits received	Total liabilities from financial activities.
January 1, 2025	\$ 1,381,789	\$ 88,992	\$ 1,315,500	\$ 354,275	\$ 28,575	\$ 3,169,131
Borrowing/ Increase	1,084,749	527,008	140,000	46,329	-	1,798,086
Repayment/ Payment	( 586,987)	( 239,000)	( 1,032,600)	( 24,414)	( 2,396)	( 1,885,397)
Changes from non-cash items	-	-	-	( 10,608)	-	( 10,608)
Changes in exchange rate	-	-	-	( 2,810)	( 2,360)	( 5,170)
June 30, 2025	<u>\$ 1,879,551</u>	<u>\$ 377,000</u>	<u>\$ 422,900</u>	<u>\$ 362,772</u>	<u>\$ 23,819</u>	<u>\$ 3,066,042</u>

	Shot-term borrowings	Short-term notes payable	Long-term borrowings	Lease liabilities	Deposits received	Total liabilities from financial activities.
January 1, 2024	\$ 1,519,513	\$ 110,884	\$ 1,449,000	\$ 358,343	\$ 19,566	\$ 3,457,306
Borrowing/ Increase	754,700	756,000	320,000	23,450	5,456	1,859,606
Repayment/ Payment	( 1,019,500)	( 200,884)	( 946,500)	( 21,919)	-	( 2,188,803)
Changes in exchange rate	-	-	-	926	537	1,463
June 30, 2024	<u>\$ 1,254,713</u>	<u>\$ 666,000</u>	<u>\$ 822,500</u>	<u>\$ 360,800</u>	<u>\$ 25,559</u>	<u>\$ 3,129,572</u>

## 7. Related party transactions

### (1) Name and relationship of related parties

<u>Name</u>	<u>Relationship with the Group</u>
Chunghwa Chemical Synthesis & Biotech Co., Ltd. (CCSB)	Associate of The Group
Sino-Japan Chemical Co., Ltd. (Sino-Japan Chemical)	Associate of The Group
PHERMPEP CO., LTD. (PHERMPEP)	Associate of The Group
Wuxi Jirui Medical Technology Co., Ltd. (Wuxi Jirui)	Associate of The Group
Trium Therapeutics Co., Ltd(Trium)	The Group's joint venture (Note)
HU-YU CO., LTD (HU-YU)	The individual controlled by major management team of The Group
Markart Enterprise Co., Ltd. (Markart)	The individual controlled by major management team of The Group
Sela Holdings Inc.	The individual controlled by major management team of The Group
Cafe Warm Up Occupational Therapy Center (Cafe Warm Up)	Other related parties

Note: Discontinued on May 24, 2024.

### (2) Major transactions with related parties

#### 1. Operating revenue

	<u>April 1 to June 30, 2025</u>	<u>April 1 to June 30, 2024</u>
Merchandising:		
One of the individuals controlled by the major management team		
— HU-YU	\$ 33,699	\$ 42,320
Affiliated enterprises	2,910	2,076
	<u>\$ 36,609</u>	<u>\$ 44,396</u>

	January 1 to June 30, 2025	January 1 to June 30, 2024
Merchandising:		
One of the individuals controlled by the major management team		
– HU-YU	\$ 79,482	\$ 103,352
– Markart	2	-
Affiliated enterprises	2,933	2,103
	<u>\$ 82,417</u>	<u>\$ 105,455</u>

- (1) The transaction price for the joint replacement products that CCPC sells is made by the individual controlled by the major management team based on the import cost plus 4%. Due to the industry peculiarities, the payment is Net 240 days which is longer than the general transactions.
- (2) The payment term of The Group for general customers is 120 days to 180 days. Except for the previous statement, the payment term and transaction price for related party is relevant to customers at the same level, however, part of the payment is still being delayed.

## 2. Purchases

	April 1 to June 30, 2025	April 1 to June 30, 2024
Purchase of goods:		
Affiliated enterprises	\$ 4,736	\$ 7,465
	<u>January 1 to June 30, 2025</u>	<u>January 1 to June 30, 2024</u>
Purchase of goods:		
Affiliated enterprises	\$ 20,280	\$ 17,123

The purchase from The Group to the related party is based on the general commercial conditions, and the payment is 3~4 months with remittance after purchasing. However, part of payment is still delayed.

## 3. Accounts receivable and notes

	June 30, 2025	December 31, 2024	June 30, 2024
Accounts receivable and notes:			
The individual controlled by major management team- HU-YU	\$ 105,606	\$ 244,420	\$ 193,361
Affiliated enterprises	3,039	31	2,169
	108,645	244,451	195,530
Less: Allowance for losses	( 15,841)	( 36,663)	( 29,028)
Total	<u>\$ 92,804</u>	<u>\$ 207,788</u>	<u>\$ 166,502</u>

- (1) In general, the Company grants payment periods ranging from 120 days to 180 days for general customers, and 240 days for individual entities controlled by the key management. For financial instruments dated beyond the aforementioned payment period, the Board resolved to treat as loans, and has been recognized as “other receivables -related parties”. These loans are accompanied by the letter of surety issued by the Chairman of the Company. For additional information, refer to Note 7 (2) 5 (1), “entities controlled by key management”.
- (2) Account and note receivables as of June 30, 2025, December 31 and June 30, 2024 were from customer contracts. Account receivables and the associated allowed made stood at NTD 240,820 and NTD 36,122, respectively, on January 1, 2024.
- (3) The exposure amounts of the maximum credit risk which can represent the accounts receivable and bill receivable of the Group's related parties without considering the possessed collateral or other credit enhancement condition on June 30, 2025, December 31 and June 30, 2024 are its book amount .
- (4) The aging analysis of accounts receivable and bill receivable is as follows:

	June 30, 2025		December 31, 2024	
	Accounts receivable	Notes receivable	Accounts receivable	Notes receivable
Not-overdue	\$ 56,291	\$ 52,354	\$ 22,184	\$ 97,288
Overdue within 1-90 days	-	-	-	54,776
Overdue within 91-180 days	-	-	-	70,203
	<u>\$ 56,291</u>	<u>\$ 52,354</u>	<u>\$ 22,184</u>	<u>\$ 222,267</u>
			June 30, 2024	
			Accounts receivable	Notes receivable
Not-overdue			<u>\$ 36,125</u>	<u>\$ 159,405</u>

#### 4. Accounts payable

	June 30, 2025	December 31, 2024	June 30, 2024
Accounts payable:			
Affiliated enterprises	<u>\$ 20,909</u>	<u>\$ 14,412</u>	<u>\$ 13,093</u>

The purchase from The Group to the related party is based on the general commercial conditions, and the payment is 3~4 months with remittance after purchasing. However, part of payment is still delayed.

5. Other receivable

(1) A. Related party of the loan funds.

	<u>June 30, 2025</u>	<u>December 31, 2024</u>	<u>June 30, 2024</u>
The individual controlled by major management team- HU-YU			
Overdue accounts receivable and notes receivable	\$ 158,286	\$ 159,342	\$ 206,565
transferred to other receivables			
Financing amount receivable	<u>142,000</u>	<u>101,000</u>	<u>80,000</u>
	300,286	260,342	286,565
Less: Allowance for losses	<u>( 23,743)</u>	<u>( 23,901)</u>	<u>( 30,985)</u>
	<u>\$ 276,543</u>	<u>\$ 236,441</u>	<u>\$ 255,580</u>

B. Interest income

	<u>April 1 to June 30, 2025</u>	<u>April 1 to June 30, 2024</u>
The individual controlled by major management team- HU-YU	<u>\$ 1,494</u>	<u>\$ 1,421</u>
	<u>January 1 to June 30, 2025</u>	<u>January 1 to June 30, 2024</u>
The individual controlled by major management team- HU-YU	<u>\$ 2,822</u>	<u>\$ 2,779</u>

(2) Interest receivable, rent receivable, labor service and collection and payment transfer.

	<u>June 30, 2025</u>	<u>December 31, 2024</u>	<u>June 30, 2024</u>
The individual controlled by major management team- HU-YU	\$ 444	\$ -	\$ -
Affiliated enterprises	<u>8</u>	<u>9</u>	<u>37</u>
	<u>\$ 452</u>	<u>\$ 9</u>	<u>\$ 37</u>

6. Acquisition of financial assets

	Account titles in book	Number of shares	Object of transaction	January 1 to June 30, 2025	
				Prices of acquisitions	
Affiliate -Wuxi Jirui Medical Technology Co., Ltd.	Investment under the equity method	-	Wuxi Jirui Medical Technology Co., Ltd. (Wuxi Jirui)	\$	463

For the three months and six months ended June 30, 2025 and 2024: none.

7. Disposal of financial assets

	Account titles in book	Number of shares traded (thousand shares)	Object of transaction	January 1 to May 24, 2024	
				Proceeds from disposals	Disposal (Loss) gain
Joint venture-Trium	Investment accounted for under the equity method	8,000	Trium Therapeutics Co., Ltd	\$ 25,349	\$ -

On May 24, 2024, the Group and all the joint ventures resolved to dissolve Trium Therapeutics Co., Ltd. and on May 28, 2024, NTD 25,349 was recovered for the investment.

For the three months and the six months ended June 30, 2025: none.

8. Provide the endorsement guarantee status of the related party

	June 30, 2025	December 31, 2024	June 30, 2024
The individual controlled by major management team-HU-YU	\$ 158,300	\$ 252,600	\$ 300,300

Among the endorsement guarantees of the Group as of June 30, 2025, the Group's actual guarantee exposure to Hu Yu Co., Ltd. was NTD 158,300.

9. Others

For the Group's dividend from the associates, please refer to Note 6(7)(2)

(3) Remuneration to key management

	April 1 to June 30, 2025	April 1 to June 30, 2024
Short-term employee benefits	\$ 24,837	\$ 23,318
Retirement benefits	426	425
	<u>\$ 25,263</u>	<u>\$ 23,743</u>
	January 1 to June 30, 2025	January 1 to June 30, 2024
Short-term employee benefits	\$ 50,918	\$ 50,834
Retirement benefits	675	819
	<u>\$ 51,593</u>	<u>\$ 51,653</u>

8. Pledged assets

The assets of the Group are offered as collateral as follows:

Asset Item	Book Value			Purpose of guarantee
	June 30, 2025	December 31, 2024	June 30, 2024	
Land, buildings and structures (recognized in property, plant, and equipment and investment property)	\$ 2,673,092	\$ 2,647,454	\$ 2,738,381	Long-term and short-term loan, purchase...etc.
Refundable deposits (recognized in other non-current assets)	63,556	55,993	77,630	Leasing security deposits, bid bonds, and court deposits
	<u>\$ 2,736,648</u>	<u>\$ 2,703,447</u>	<u>\$ 2,816,011</u>	

9. Significant contingent liabilities and unrecognized contractual commitments

(1) Contingencies

In February 2025, the Company received a letter from the Securities and Futures Investors Protection Center, claiming that the subsidiary CCPC should compensate the counterparty, which the Supreme Court has enforced. The Company is currently in the process of negotiating with the lawyer on the subsequent compulsory enforcement.

(2) Commitments

1. The Company has signed contracts for the purchase of machine and equipment, construction work for the plant, intangible assets and consulting service with outstanding payment amounting to NTD 138,616, NTD 207,936 and NTD 273,412 as of June 30, 2025, December 31 and June 30, 2024, respectively. In the contract of consultation services, part of the performance expenses are paid according to the plan benefits.
2. The unused L/C balance as of June 30, 2025, December 31 and June 30, 2024 were NTD 47,426, NTD 51,002 and NTD 38,860 respectively.
3. The amounts issued as of June 30, 2025, December 31 and June 30, 2024 were NTD 3,587,840, NTD 3,951,000, and NTD 4,020,720, respectively.

10. Significant disaster loss

No such event

11. Significant subsequent events

- (1) The Company's RSAs became effective following approval by the Financial Supervisory Commission on July 21, 2025. On August 8, 2025, the Board of Directors approved the issuance of 725 thousand shares, with August 8, 2025 as the record date for the capital increase.
- (2) The Company's Board of Directors resolved on August 8, 2025, to buy back treasury shares for transfer to employees. The buyback period is expected to run from August 11 to October 9, 2025, with a total of 1,000 thousand shares to be repurchased at a price range of NTD 25 to NTD 43 per share; however, shares may still be repurchased at prices below this range.

12. Others

(1) Capital management

The Group's capital risk management objectives are to ensure that the Group is capable of continuing operations, to maintain the most appropriate capital structure in order to reduce cost of capital and to maximize returns for shareholders. The Group may make adjustments to dividends paid to shareholders, refund capital to shareholders, issue new shares or sell assets to reduce the level of debts in order to maintain or adjust the Group's capital structure. The Group uses the debt-to-equity ratio to monitor its capital. The ratio is calculated by dividing net debts by total capital. Net debts are calculated as total debts (including "current and non-current borrowings" presented in the consolidated balance sheet) less cash and cash equivalents. Total capital is calculated as "equity" presented in the consolidated balance sheet plus net debts.

The strategy of the Group in 2025 is the same as that in 2024, which is dedicated to maintain the debt-to-capital ratio to 40% below. The debt-to-capital ratio of the Group on June 30, 2025, December 31 and June 30, 2024 were as follows:

	<u>June 30, 2025</u>	<u>December 31, 2024</u>	<u>June 30, 2024</u>
Total loan amount	\$ 2,679,451	\$ 2,786,281	\$ 2,743,213
Less: Cash and cash equivalent	<u>( 684,064)</u>	<u>( 588,011)</u>	<u>( 451,000)</u>
Net debt	1,995,387	2,198,270	2,292,213
Total equity	<u>7,384,670</u>	<u>7,549,351</u>	<u>7,441,687</u>
Total capital	<u>\$ 9,380,057</u>	<u>\$ 9,747,621</u>	<u>\$ 9,733,900</u>
Liability/assets ratio	21%	23%	24%

(2) Financial instruments

1. Categories of financial instruments

	<u>June 30, 2025</u>	<u>December 31, 2024</u>	<u>June 30, 2024</u>
<u>Financial assets</u>			
Financial assets at fair value through profit and loss			
Financial assets mandatorily measured at fair value through profit or loss	\$ -	\$ -	\$ 44,523
Financial assets at fair value through other comprehensive profit or loss			
Select the designated equity instrument investment.	181,419	329,968	397,974
Financial assets measured at the amortized cost			
Cash and cash equivalents	684,064	588,011	451,000
Financial assets measured at the amortized cost	88,414	95,413	93,013
Notes receivable	436,350	496,315	577,598
Accounts receivable	1,519,733	1,494,754	1,554,251
Other receivables	295,221	259,168	277,930
Refundable deposits	63,556	55,993	77,630
	<u>\$ 3,268,757</u>	<u>\$ 3,319,622</u>	<u>\$ 3,473,919</u>
	<u>June 30, 2025</u>	<u>December 31, 2024</u>	<u>June 30, 2024</u>
<u>Financial liabilities</u>			
Financial liability measured at the amortized cost			
Short-term borrowings	\$ 1,879,551	\$ 1,381,789	\$ 1,254,713
Short-term notes payable	377,000	88,992	666,000
Payable notes	-	1,208	2,718
Accounts payable	726,719	908,706	842,828
Other payables	811,952	756,753	758,957
Deposits received	23,819	28,575	25,559
Long-term payables (recognized in other non-current liabilities)	8,299	8,299	8,299
The long-term loan (including the expiration of one year or an operating cycle).	422,900	1,315,500	822,500
	<u>\$ 4,250,240</u>	<u>\$ 4,489,822</u>	<u>\$ 4,381,574</u>
Lease liability (including current and non-current)	<u>\$ 362,772</u>	<u>\$ 354,275</u>	<u>\$ 360,800</u>

## 2. Risk management policies

- (1) The daily operation of The Group is affected by multiple financial risks, which include the market risk (currency risk, interest rate risk and price risk), credit risk and liquidity risk. The overall risk management policy of The Group is to focus on the unpredictable matters of the financial market and seek for the method to decrease the potential adverse impact on the financial situation and financial performance of The Group.
- (2) The risk management is executed by the financial center of The Group according to the policies approved by the board of directors. The financial center of the group works close with the operation unit of The Group to identify, evaluate and avoid risk. The board of director also sets the written principle for the overall management risk and provides a written policy for specific scope and matters, ex. currency risk, interest rate risk, credit risk, use of derivative and non-derivative financial instruments as well as the investment of the remaining liquidity.

## 3. Nature and degree of the significant financial risk.

### (1) Market Risk

#### Exchange rate risk

- A. The operation of the Group is transnational, which suffers from the currency occurred by multiple currencies and the majority is USD, RMB and JPY. The relevant currency risk comes from the future commercial deals, recognized assets and liability as well as the net investment of the foreign operation.
- B. The business of the Group involves several non-functional currencies (the functional currency of the Company and some subsidiaries is NTD, while that of some subsidiaries are RMB), and therefore are affected by the exchange rate fluctuation, the information about the currency with significant exchange rate fluctuation is as follows:

	June 30, 2025		
	Foreign currency (NTD thousand)	Exchange rate	Book value (NTD)
(Foreign currency: Functional currency)			
<u>Financial assets</u>			
<u>Monetary items</u>			
JPY: NTD	\$ 429,126	0.2037	\$ 87,413
USD: NTD	1,547	29.28	45,296
JPY: RMB	18,536	0.0498	3,775
USD: RMB	3,025	7.16	88,585
<u>Financial liabilities</u>			
<u>Monetary items</u>			
JPY: NTD	\$ 92,036	0.2037	\$ 18,748
USD: NTD	2,888	29.28	84,561

December 31, 2024			
	Foreign currency (NTD thousand)	Exchange rate	Book value (NTD)
(Foreign currency: Functional currency)			
<u>Financial assets</u>			
<u>Monetary items</u>			
JPY: NTD	\$ 219,637	0.2101	\$ 46,146
USD: NTD	807	32.78	26,453
JPY: RMB	16,314	0.0469	3,426
USD: RMB	1,870	7.32	61,297
<u>Financial liabilities</u>			
<u>Monetary items</u>			
JPY: NTD	\$ 86,843	0.2101	\$ 18,246
USD: NTD	2,263	32.78	74,181

June 30, 2024			
	Foreign currency (NTD thousand)	Exchange rate	Book value (NTD)
(Foreign currency: Functional currency)			
<u>Financial assets</u>			
<u>Monetary items</u>			
JPY: NTD	\$ 199,394	0.2018	\$ 40,238
USD: NTD	482	32.43	15,631
JPY: RMB	19,011	0.0454	3,835
USD: RMB	1,163	7.30	37,729
<u>Financial liabilities</u>			
<u>Monetary items</u>			
JPY: NTD	\$ 54,771	0.2018	\$ 11,053
USD: NTD	4,025	32.43	130,531

- C. The amounts of the unrealized gains and losses with significant exchange rate fluctuation for the currency of the Group recognized for the three months and six months ended June 30, 2025 and 2024 were summed amount respectively as NTD (7,689), NTD 12,031, NTD (3,971) and NTD 12,304.
- D. The analysis of foreign exchange risk affected by significant exchange rate fluctuation for the Group is as follows.

January 1 to June 30, 2025				
Sensitivity analysis				
	Magnitude changes		Influence of profit and loss	The impact of other comprehensive profit or loss
(Foreign currency: Functional currency)				
<u>Financial assets</u>				
<u>Monetary items</u>				
JPY: NTD	1%	\$	874	\$ -
USD: NTD	10%		4,530	-
JPY: RMB	1%		38	-
USD: RMB	10%		8,859	-
<u>Financial liabilities</u>				
<u>Monetary items</u>				
JPY: NTD	1%	\$	187	\$ -
USD: NTD	10%		8,456	-

January 1 to June 30, 2024				
Sensitivity analysis				
	Magnitude changes		Influence of profit and loss	The impact of other comprehensive profit or loss
(Foreign currency: Functional currency)				
<u>Financial assets</u>				
<u>Monetary items</u>				
JPY: NTD	1%	\$	402	\$ -
USD: NTD	10%		1,563	-
JPY: RMB	1%		38	-
USD: RMB	10%		3,773	-
<u>Financial liabilities</u>				
<u>Monetary items</u>				
JPY: NTD	1%	\$	111	\$ -
USD: NTD	10%		13,053	-

Price risk

- A. The equity instrument exposed to price risk of The Group means all financial assets listed in the account at fair value through other comprehensive income. To manage the price risk for the investment of equity instrument, The Group will break down the investment portfolio which is followed by the limited amount set by The Group.

- B. The Group mainly invests in the domestic listed and unlisted equity instrument, the price of such equity instrument will be affected by the uncertainty of the future value of that investment object. Assuming that all other conditions remain unchanged, if the price of the aforementioned equity instruments hikes or declines by 1%, the net profit, classified as the profit or loss from equity investments measured at fair value through profit or loss, for the six months ended June 30, 2025 and 2024 were estimated to increase or decrease by NTD 0 and NTD 445, respectively. Other comprehensive income, classified as the profit or loss from equity investment measured at fair value through other comprehensive income, for the six months ended June 30, 2025 and 2024 were estimated to decrease or increase by NTD 1,814 and NTD 3,980, respectively.

Cash flows and the interest risk of fair value

- A. The interest risk of The Group comes from the long-term loan, short-term loan and short-term bills receivable. The Group suffers from the interest rate risk of the cash flows based on the loan issued according to floating rate, part of the risk is being offset with the cash and cash equivalents based on the floating rate. The Group suffers from the interest rate risk of the fair value with the loan issued based on the fixed rate. The loan of The Group is mainly with floating rate. The loan amount of the Group for the six months ended June 30, 2025 and 2024 were based on the floating rate in NTD and US dollars.
- B. For the six months ended June 30, 2025 and 2024, if the change in loan interest rates is 0.1%, and all other elements are remained the same, net incomes for the six months ended June 30, 2025 and 2024 will respectively decreases NTD 1,072 and NTD 1,097 mainly because of the increase or decrease of the interest for the loan of floating interest.

(2) Credit Risk

- A. The credit risk of the Group is the risk deriving from the financial loss caused by the failure of the customers or the counterparties of trade in financial instruments in performing their contractual obligations, and is mainly from the cash flow from the contracts of the account receivable that cannot be settled by the counterparties in accordance with the terms and conditions of payment, and is classified as cash flow from contracts of investment in debt instruments measured on the basis of amortized cost.
- B. The Group established credit risk management in view of a group. According to the credit policy specified internally, before setting the payment, delivery terms and conditions with the new customer, each operating individual in the group should manage and proceed with the credit risk analysis. The internal risk management is to evaluate the credit quality of the customer in consideration of the financial situation, previous experience and other factors. The limited amount of the individual risk is set by the board of director according to the internal or external rating and monitored with the use of the credit line regularly.
- C. The Group adopts IFRS 9 to provide the following assumption as the basis to judge if the credit risk of the financial instrument significantly increases since initial recognition:

The credit risk of a financial asset is deemed to increase significantly since the recognition when a contract payment is 30 day past due.

- D. The Group adopts IFRS 9 to provide the assumption and based on actual receipt of payment previously that if the payment term in the contract exceeding 91-180 days, it will be considered as violation.
- E. The indicators used by the Group to determine the credit impairment of debt instrument investment are as follows:
- (A) The issuer is likely to enter into bankruptcy or other financial restructuring if it is experiencing major financial difficulties;
  - (B) The issuer makes the active market of the financial asset disappear due to financial difficulties;
  - (C) The issuer delays or fails to pay interest or principal;
  - (D) Changes in national or regional economic conditions that are related to the issuer's default.
- F. The Group classifies the accounts receivable of the customers according to the features of customer type with simplified method to prepare matrix and loss-rate approach as a base to estimate the expected credit loss.
- G. With the recourse process, The Group writes off the receivable amount of the financial assets which can't be expected reasonably, however, The Group will still proceed with the low process for recourse to reserve the equity of liability. By June 30, 2025, December 31 and June 30, 2024, the Group did not have the liability for creditor's with recourse write-off.
- H. The bill receivable and allowance account for change in loss of The Group is as follows:
- (1) The associates of the Group are with excellent credits; therefore, the expected loss rate is 0.2%, and the total carrying amounts of accounts receivable and other receivables as of June 30, 2025, December 31 and June 30, 2024 were NTD 3,039, NTD 31, NTD 2,169, and NTD 8, NTD 9, and NTD 37 respectively, and no allowance for losses was provided.
  - (2) The expected loss rate for the individual of the management team of the Group is 15%, and the total carrying amounts and allowances for loss on June 30, 2025, December 31 and June 30, 2024 are as follows:

Account and note receivables:	June 30, 2025	December 31, 2024	June 30, 2024
One of the individuals controlled by the major management team	\$ 105,606	\$ 244,420	\$ 193,361
Less: Allowance for losses	(15,841)	(36,663)	(29,028)
	<u>\$ 89,765</u>	<u>\$ 207,757</u>	<u>\$ 164,333</u>
 Other receivables:	 June 30, 2025	 December 31, 2024	 June 30, 2024
One of the individuals controlled by the major management team	\$ 300,730	\$ 260,342	\$ 286,565
Less: Allowance for losses	(23,743)	(23,901)	(30,985)
	<u>\$ 276,987</u>	<u>\$ 236,441</u>	<u>\$ 255,580</u>

- (3) The Group adjusts the loss rate established according to the historical and current information in a specific period of time in consideration of the completeness of vision, to estimate the bill receivable and allowance for loss. The prepared matrix of June 30, 2025, December 31 and June 30, 2024 are as follows:

	<u>Not- overdue</u>	<u>1 to 90 days overdue.</u>	<u>91 to 180 days overdue.</u>	<u>Overdue exceeding 181 days</u>	<u>Total</u>
<u>June 30, 2025</u>					
Expected rate of loss	0.02%~0.5%	0.02%~11.76%	0.02%~100%	100%	
Total amount of the book value	\$ 1,973,934	\$ 21,854	\$ 7,868	\$ 2,808	\$ 2,006,464
Allowance for losses	3,395	995	2,788	2,808	9,986
	<u>Not- overdue</u>	<u>1 to 90 days overdue.</u>	<u>91 to 180 days overdue.</u>	<u>Overdue exceeding 181 days</u>	<u>Total</u>
<u>December 31, 2024</u>					
Expected rate of loss	0.02%~0.91%	0.02%~18.56%	0.02%~100%	100%	
Total amount of the book value	\$ 1,903,458	\$ 18,550	\$ 2,925	\$ 538	\$ 1,925,471
Allowance for losses	8,105	1,133	2,377	538	12,153
	<u>Not- overdue</u>	<u>1 to 90 days overdue.</u>	<u>91 to 180 days overdue.</u>	<u>Overdue exceeding 181 days</u>	<u>Total</u>
<u>June 30, 2024</u>					
Expected rate of loss	0.02%~0.91%	0.02%~18.56%	0.02%~100%	100%	
Total amount of the book value	\$ 2,079,853	\$ 14,381	\$ 1,549	\$ 762	\$ 2,096,545
Allowance for losses	6,378	41	276	762	7,457

- I. The change in allowance for loss table for bill receivable, accounts receivable and other accounts receivable by the Group are as follows:

	<u>2025</u>	
	<u>Note receivable and accounts receivable</u>	<u>Other receivables</u>
January 1	\$ 48,816	\$ 23,901
Impairment loss reversal	( 22,534)	-
Reclassification	158	( 158)
Foreign exchange impact amount	( 613)	-
June 30	<u>\$ 25,827</u>	<u>\$ 23,743</u>

	2024	
	Note receivable and accounts receivable	Other receivables
January 1	\$ 44,719	\$ 28,378
Impairment loss reversal	( 5,672)	-
Reclassification	( 2,607)	2,607
Foreign exchange impact amount	45	-
June 30	<u>\$ 36,485</u>	<u>\$ 30,985</u>

(3) Liquidity risk

- A. The prediction of cash flows is executed by each operating unit in the group and summarized by the financial center of the group. The financial center of the group monitors the prediction for the liquidity requirement of the group, to ensure the capital is sufficient to support the operation requirements.
- B. The below table is the derivative financial liabilities of The Group, which is classified based on the due date. The derivative financial liabilities are analyzed according to the remaining period between the date of balance sheet to the expiry date of the contract. The amount of the cash flows in the contract disclosed by the following table is the undiscounted amount.

Non-derivative financial liabilities:

June 30, 2025	Less than 3 months	3 months to 1 year	1 to 2 years	2 to 5 years	Over 5 year
Shot-term borrowings	\$ 545,836	\$ 1,338,565	\$ -	\$ -	\$ -
Short-term notes payable	377,000	-	-	-	-
Accounts payable	625,318	101,401	-	-	-
Other payables	770,657	41,295	-	-	-
Lease liabilities	14,157	42,826	62,698	141,904	129,127
Long-term payables	-	-	1,953	5,858	488
Long-term borrowings	1,830	26,758	372,468	31,709	-
Deposits received	-	22,487	1,332	-	-
Financial commitment agreements	158,300	-	-	-	-

Non-derivative financial liabilities:

December 31, 2024	Less than 3 months	3 months to 1 year	1 to 2 years	2 to 5 years	Over 5 year
Shot-term borrowings	\$ 83,746	\$ 1,303,132	\$ -	\$ -	\$ -
Short-term notes payable	39,000	50,000	-	-	-
Payable notes	755	453	-	-	-
Accounts payable	749,274	159,432	-	-	-
Other payables	640,083	116,670	-	-	-
Lease liabilities	13,604	39,986	52,711	121,044	150,280
Long-term payables	-	-	1,953	5,858	488
Long-term borrowings	10,106	22,459	1,228,905	66,845	-
Deposits received	-	27,243	-	1,332	-
Financial commitment agreements	173,300	-	-	-	-

Non-derivative financial liabilities:

June 30, 2024	Less than 3 months	3 months to 1 year	1 to 2 years	2 to 5 years	Over 5 year
Shot-term borrowings	\$ 375,625	\$ 882,180	\$ -	\$ -	\$ -
Short-term notes payable	189,000	477,000	-	-	-
Payable notes	755	1,963	-	-	-
Accounts payable	682,031	160,797	-	-	-
Other payables	691,942	67,015	-	-	-
Lease liabilities	13,584	40,859	52,937	133,111	150,093
Long-term payables	-	-	1,953	5,858	488
Long-term borrowings	2,481	14,349	819,515	-	-
Deposits received	-	24,869	-	690	-
Financial commitment agreements	214,300	-	-	-	-

(3) Fair value information

1. For the Group's financial assets and liabilities not measured at fair value, including cash and cash equivalents, financial assets measured at amortized cost -current, bills receivable, accounts receivable, other receivables, refundable deposits, short-term borrowings, short-term bills payable, notes payable, accounts payable, other payables, deposits received, long-term payables, long-term borrowings (including long-term borrowings due within one

year or within the Group's operating cycle) and lease liabilities, the amount is a reasonable approximation of fair value. Please refer to Note 12 (2) 1. for details.

2. The valuation technique for measuring the fair value of financial and non-financial instruments is defined as follows:

Level 1: The quotation (unadjusted) of the same assets or liabilities that can be acquired by the company in an active market on the measurement date. An active market refers to the market with sufficient frequency and quantity of the assets or liabilities transactions took place in order to provide market pricing information constantly. The fair value of the stock investment for the listed stock invested by The Group is all included.

Level 2: It refers to the directly or indirectly observable input value of asset or liability, except for those quotations included in Level 1. The fair value of structured deposits invested by the Group and embedded in derivatives is within this level.

Level 3: The unobservable inputs of assets or liabilities.

3. The fair value of investment property calculated by cost method is NTD 206,254, which was estimated based on the market price of similar properties in the vicinity.

4. The Group's financial and non-financial instruments measured at fair value are classified by the nature of assets and liabilities, characteristics and risks, and fair value as follows:

- (1) The relevant information about the classification of the nature for the assets and liabilities of The Group is as follows:

June 30, 2025	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Assets				
<u>Repeatable fair value</u>				
Investment of equity instruments at fair value through other comprehensive income	<u>\$ 97,800</u>	<u>\$ -</u>	<u>\$ 83,619</u>	<u>\$ 181,419</u>
December 31, 2024	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Assets				
<u>Repeatable fair value</u>				
Investment of equity instruments at fair value through other comprehensive income	<u>\$ 231,545</u>	<u>\$ -</u>	<u>\$ 98,423</u>	<u>\$ 329,968</u>
June 30, 2024	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Assets				
<u>Repeatable fair value</u>				
Financial assets at fair value through profit and loss	<u>\$ 44,523</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 44,523</u>

Repeatable fair value

Investment of equity instruments at fair value through other comprehensive income	<u>\$ 312,433</u>	<u>\$ -</u>	<u>\$ 85,541</u>	<u>\$ 397,974</u>
---	-------------------	-------------	------------------	-------------------

(2) The methods and assumptions used by the Group to measure fair value are described as follows:

A. The Group adopts the market quotation as the input value for the fair value (which is the first class), the classification according to the feature of the tool is as follows:

Market quotation	<u>Listed (OTC) and emerging stocks</u> Closing price
------------------	--

B. Besides the financial instrument of the active market as stated above, the fair value of other financial instrument is obtained by evaluation technique or reference of the counter party.

C. While evaluating the financial instrument which is non-standardized and with low complexity, The Group adopts the evaluation technique which is comprehensively used by the market participants. The parameter used for the valuation model of such financial instrument is usually the observable information of the market.

D. What the valuation model comes out is the estimated value, and the evaluation technique can't reflect all relating factors of the financial instrument and non-financial instrument of The Group. Therefore, the estimated value of the valuation model will be adjusted based on the additional parameter properly, such as the model risk or liquidity risk...etc. According to the management policy and relevant control program of the valuation model for fair value of The Group, the management team believes it is appropriate and necessary to adjust the evaluation for expressing the fair value of the financial instrument and non-financial instrument in the aggregate balance sheet. The price information and parameter used in the valuation process is evaluated prudently and adjusted according to the current market situation properly.

5. The changes in Level 6 for the six months ended June 30, 2025 and 2024, respectively, are described as follows:

	<u>2025</u>	<u>2024</u>
	<u>Equity instruments</u>	<u>Equity instruments</u>
January 1	\$ 98,423	\$ 97,898
Increase of the current period	97	-
Evaluation adjustment	( 11,022)	( 13,507)
Foreign exchange impact amount	<u>( 3,879)</u>	<u>1,150</u>
June 30	<u>\$ 83,619</u>	<u>\$ 85,541</u>

6. The valuation process for classifying the fair value to the third level of The Group is proceeded by the financial center for the independent fair value valuation of the financial instrument, by using the independent sources to have the valuation result close to the market status, and make sure that the sources of the information is independent, reliable and consistent with other resources as well as all other necessary adjustment of fair value, to ensure the valuation result is reasonable.

Besides, the valuation policy, valuation process and confirmation for the fair value of the financial instrument set by the Ministry of Finance meet the regulations of relevant international financial reporting standards.

7. The sensitivity analysis explanation of the quantitative data of significant non-observable input value and change of significant non-observable input value which belongs to the valuation model for the items to review the third level of fair value is as follows:

	Fair value on June 30, 2025	Valuation technique	Significant unobservable input value	Relationship between input value and fair value
Stock of the venture capital	\$ 83,619	Net assets value method	Not applicable	Not applicable
	Fair value on December 31, 2024	Valuation technique	Significant unobservable input value	Relationship between input value and fair value
Stock of the venture capital	\$ 98,423	Net assets value method	Not applicable	Not applicable
	Fair value on June 30, 2024	Valuation technique	Significant unobservable input value	Relationship between input value and fair value
Stock of the venture capital	\$ 85,541	Net assets value method	Not applicable	Not applicable

8. The valuation and valuation parameter chosen by The Group is evaluated properly, however, the different valuation model or valuation parameter may lead in different valuation result.

### 13. Notes of disclosure

#### (1) Information about important transactions

According to the “Regulations Governing the Preparation of Financial Reports by Securities Issuers.” The significant transaction matters of The Company for the six months ended June 30, 2025 were as follows:

1. The Loaning of funds: Please see attached table 1.
2. Endorsement and Guarantee: Please see attached table 2.
3. Major securities held at the end of the period (excluding investments in subsidiaries,

affiliates, and joint ventures): Please see attached table 3.

4. Purchase from or sale to related parties for an amount exceeding NTD 100 million or 20% of paid-in capital: Please see attached table 4.
5. Amounts receivable from related parties totaling more than NTD 100 million or 20% of paid up capital: Please see attached table 5.
6. Business relationships and significant transactions between the parent company and its subsidiaries: Please refer to attached table 6.

(2) Information related to reinvested enterprises

The relevant information of names, area of location of the investees (excluding the investees in China), please see attached table 7.

(3) Information about investment in mainland China

1. Basic information: Please see attached table 8.
2. Significant transactions with investee companies in the Mainland China, either directly or indirectly through a third country: Not applicable.

14. Segment information

(1) General information

The management team of The Company has identified the reportable segments according to the information used in making decision by the board of director.

The board of director of The Group operates and evaluates the segments performance in view of the regional diversity.

(2) Segment information

The information provided for the major operation decision maker for the reportable segments is as follows:

<u>April 1 to June 30,</u> <u>2025</u>	<u>Taiwan</u>	<u>China</u>	<u>Adjust and eliminate</u>	<u>Total</u>
External revenue	\$ 1,733,475	\$ 373,561	\$ -	\$ 2,107,036
Inter-segment income	<u>739,815</u>	<u>-</u>	<u>( 739,815)</u>	<u>-</u>
Revenue of the reportable segments.	<u>\$ 2,473,290</u>	<u>\$ 373,561</u>	<u>(\$ 739,815)</u>	<u>\$ 2,107,036</u>
Pre-tax net income of the segments before being adjusted	\$ 269,750	(\$ 40,281)	(\$ 131,401)	\$ 98,068
Investment profit or loss recognized according to the Equity Method	<u>73,928</u>	<u>( 2,255)</u>	<u>( 85,925)</u>	<u>( 14,252)</u>
Pre-tax net income of the reportable segments	<u>\$ 343,678</u>	<u>(\$ 42,536)</u>	<u>(\$ 217,326)</u>	<u>\$ 83,816</u>
Profits or losses of the segments include:				
Depreciation and amortization	<u>\$ 74,971</u>	<u>\$ 12,204</u>		<u>\$ 87,175</u>

<u>April 1 to June 30,</u> <u>2024</u>	<u>Taiwan</u>	<u>China</u>	<u>Adjust and eliminate</u>	<u>Total</u>
External revenue	\$ 1,713,737	\$ 501,985	\$ -	\$ 2,215,722
Inter-segment income	<u>678,813</u>	<u>-</u>	<u>( 678,813)</u>	<u>-</u>
Revenue of the reportable segments.	<u>\$ 2,392,550</u>	<u>\$ 501,985</u>	<u>(\$ 678,813)</u>	<u>\$ 2,215,722</u>
Pre-tax net income of the segments before being adjusted	\$ 96,598	(\$ 30,862)	\$ 373	\$ 66,109
Investment profit or loss recognized according to the Equity Method	<u>54,962</u>	<u>( 34)</u>	<u>( 25,672)</u>	<u>29,256</u>
Pre-tax net income of the reportable segments	<u>\$ 151,560</u>	<u>(\$ 30,896)</u>	<u>(\$ 25,299)</u>	<u>\$ 95,365</u>
Profits or losses of the segments include:				
Depreciation and amortization	<u>\$ 71,613</u>	<u>\$ 20,870</u>		<u>\$ 92,483</u>
<u>January 1 to June 30,</u> <u>2025</u>	<u>Taiwan</u>	<u>China</u>	<u>Adjust and eliminate</u>	<u>Total</u>
External revenue	\$ 3,487,429	\$ 875,235	\$ -	\$ 4,362,664
Inter-segment income	<u>1,437,732</u>	<u>-</u>	<u>( 1,437,732)</u>	<u>-</u>
Revenue of the reportable segments.	<u>\$ 4,925,161</u>	<u>\$ 875,235</u>	<u>(\$ 1,437,732)</u>	<u>\$ 4,362,664</u>
Pre-tax net income of the segments before being adjusted	\$ 424,321	(\$ 54,544)	(\$ 131,011)	\$ 238,766
Investment profit or loss recognized according to the Equity Method	<u>280,096</u>	<u>( 2,257)</u>	<u>( 285,160)</u>	<u>( 7,321)</u>
Pre-tax net income of the reportable segments	<u>\$ 704,417</u>	<u>(\$ 56,801)</u>	<u>(\$ 416,171)</u>	<u>\$ 231,445</u>
Asset of the reportable segments	<u>\$ 10,945,816</u>	<u>\$ 1,405,942</u>		<u>\$ 12,351,758</u>
Profits or losses of the segments include:				
Depreciation and amortization	<u>\$ 149,007</u>	<u>\$ 24,825</u>		<u>\$ 173,832</u>

<u>January 1 to June 30, 2024</u>	<u>Taiwan</u>	<u>China</u>	<u>Adjust and eliminate</u>	<u>Total</u>
External revenue	\$ 3,373,155	\$ 1,126,593	\$ -	\$ 4,499,748
Inter-segment income	<u>1,300,123</u>	<u>-</u>	<u>( 1,300,123)</u>	<u>-</u>
Revenue of the reportable segments.	<u>\$ 4,673,278</u>	<u>\$ 1,126,593</u>	<u>(\$ 1,300,123)</u>	<u>\$ 4,499,748</u>
Pre-tax net income of the segments before being adjusted	\$ 204,684	(\$ 23,012)	\$ 754	\$ 182,426
Investment profit or loss recognized according to the Equity Method	<u>107,589</u>	<u>( 36)</u>	<u>( 62,673)</u>	<u>44,880</u>
Pre-tax net income of the reportable segments	<u>\$ 312,273</u>	<u>(\$ 23,048)</u>	<u>(\$ 61,919)</u>	<u>\$ 227,306</u>
Asset of the reportable segments	<u>\$ 10,903,272</u>	<u>\$ 1,653,031</u>		<u>\$ 12,556,303</u>
Profits or losses of the segments include:				
Depreciation and amortization	<u>\$ 142,456</u>	<u>\$ 40,209</u>		<u>\$ 182,665</u>

(3) The adjusted information of the profits or losses of the segments

The pre-tax profit/ loss of the reportable segments is the same as that of the business segments, therefore, no adjustment has to be made.

Cenra Inc. and subsidiaries

The Loaning of Funds

January 1 to June 30, 2025

Attached table 1

Unit: NTD thousand  
(Except where otherwise stated)

No. (Note 1)	The lender of fund	The borrower of fund	Transaction title	Are they related parties	Maximum balance – current period (Note 2)	Balance, ending	The actual amounts disbursed	Interest rate collars	Nature of financing (Note 3)	Amount of business transactions	Reasons for the necessity of short-term financing	Amount of provision for bad debts	Collateral		Limit of financing particular beneficiary	Total limit of financing	Remarks
													Name	Value			
1	China Chemical & Pharmaceutical Co., Ltd.	HU-YU Co., Ltd.	Other receivables	Y	\$ 160,030	\$ 158,286	\$ 158,286	2.01%	1	\$ 158,873	-	\$ 23,743	Note 5	\$-	\$ 158,873	\$ 2,080,258	Note 4(1), (2)
1	China Chemical & Pharmaceutical Co., Ltd.	Cenra Inc.	Other receivables	Y	100,000	100,000	82,900	2.00%	2	-	Working capital	-	-	-	1,040,129	2,080,258	Note 4 (2)
2	Tairung Enterprise Co., Ltd.	HU-YU Co., Ltd.	Other receivables	Y	48,000	48,000	48,000	2.30%	2	-	Working capital	-	-	-	47,614	47,614	Note 4(3), Note 5
3	Chunghwa Yuming Healthcare Co., Ltd.	HU-YU Co., Ltd.	Other receivables	Y	94,000	94,000	94,000	2.10%	2	-	Working capital	-	-	-	103,273	206,546	Note 4(4), Note 5

Note 1: The filing method for the numbering of lending money by the Company is as follows:

- (1) Fill in 0 for the issuer.
- (2) The investees are sequentially numbered from 1 and so forth.

Note 2: Maximum balance of financing a third party in current period.

Note 3: Below are the two filing methods for the nature of lending money

- (1) With business dealings
- (2) With necessity of short-term financing

Note 4: Maximum and aggregate amount of loans made to a single entity by the Company:

- (1) Company and its subsidiaries with business transactions with the company whose individual lending amount may not exceed the most recent one year or the current year's incoming goods amount or total sales amount with the company, at the time of capital lending.
- (2) No loan made to a single entitle by China Chemical & Pharmaceutical Co., Ltd. shall exceed 15% of its net worth. Aggregated loans made shall not exceed 30% of its net worth.
- (3) No loan made to a single entitle by Tairung Enterprise Co., Ltd. shall exceed 40% of its net worth. Aggregated loans made shall not exceed 40% of its net worth.
- (4) No loan made to a single entitle by Chunghwa Yuming Healthcare Co. shall exceed 15% of its net worth. Aggregated loans made shall not exceed 30% of its net worth.

Note 5: The full value guarantee will be provided by the Chairman of The Company

Cenra Inc. and subsidiaries  
Endorsements and guarantees made for others  
January 1 to June 30, 2025

Attached table 2

Unit: NTD thousand  
(Except where otherwise stated)

No. (Note 1)	The company providing endorsement and/or guarantee	The party receiving the endorsement and/or guarantee		The limit of endorsements and/or guarantees to a single business entity	The highest balance of endorsements and/or guarantees in the current period	The ending balance of endorsements and/or guarantees	The actual amounts disbursed	Amount of property pledged for endorsements/guarantees	Total endorsements and guarantees as a percentage of equity in the most recent financial statement	The upper limit of an endorsement and/or guarantee	Guarantee and endorsement of parent company to subsidiary	Guarantee and endorsement by subsidiary to parent company	Guarantee and endorsement in Mainland China	Remarks
		Company name	Relation (Note 2)											
1	China Chemical & Pharmaceutical Co., Ltd.	HU-YU Co., Ltd.	1	\$ 158,873	\$ 237,600	\$ 158,300	\$ 158,300	\$ -	2.28%	\$ 3,467,097	N	N	N	Note 3, 4 and 5

Note 1: The column for numbering is elaborated below:

(1) Fill in 0 for the issuer.

(2) The investees are sequentially numbered from 1 and so forth.

Note 2: The 6 types of relations between the endorsement/ guarantee provider and subject of endorsement/ guarantee are as follows. Indication of types is applicable.

(1) Business relation.

(2) Subsidiary owns over 50% of ordinary equity share with direct possession.

(3) The aggregation of the ordinary share possessed by The Company and its Subsidiary exceeds 50% by the investee.

(4) The Parent Company which possesses more than 50% of the ordinary equity share directly or through its Subsidiary with indirect possession.

(5) For building construction, The Company holds a mutual guarantee with other companies based on the peer agreement:

(6) Due to the joint investment relationship, shareholders are to provide endorsement and guarantee to the company proportionately to the respective shareholding ratio.

Note 3: Endorsement and guarantee to a particular enterprise shall not exceed 30% of the net worth of the Company. The limit of endorsement and guarantee to companies in business transactions with the Company shall not exceed the amount of purchase or sale with the Company in the previous period or current period at the time of endorsement and guarantee, whichever is higher.

Note 4: The endorsement/ guarantee amount of The Company is limited to 50% of the net value of The Company.

Note 5: The highest amount of endorsement and guarantee of NTD 79,300 thousand has been reported to the Board for approval before contract renewal, and risk deriving from the undertaking of guarantee in favor of Hu Yu Co., Ltd. is NTD 158,300 thousand.

Cenra Inc. and subsidiaries

Major securities held at the end of the period (excluding investments in subsidiaries, associates, and joint ventures)

June 30, 2025

Attached table 3

Unit: NTD thousand  
(Except where otherwise stated)

Holding company	Types of negotiable securities	Names of negotiable securities (Note 1)	Relationship with the securities issuer	Account titles in book	At ending				
					Number of shares	Book value	Ratio of Shareholding	Fair value	Remarks
China Chemical & Pharmaceutical Co., Ltd.	Stock	momo.com Inc.	-	Investment of equity instruments at fair value through other comprehensive income	178,087	\$ 47,905	0.07%	\$ 47,905	None
		CDIB Capital Healthcare Ventures Limited	-	Investment of equity instruments at fair value through other comprehensive income	2,586,387	17,629	1.71%	17,629	None
	Stock	MegaPro Biomedical Co., Ltd.	Other related parties	Investment of equity instruments at fair value through other comprehensive income	2,938,458	49,895	4.54%	49,895	None
	Equity	Seraph partners	-	Investment of equity instruments at fair value through other comprehensive income	-	6,160	2.96%	6,160	None
Tairung Enterprise Co., Ltd. Suzhou Chung-hwa Chemical&pharmaceutical Industrial Co., Ltd.	Stock	Cenra Inc.	The Company	Investment of equity instruments at fair value through other comprehensive income	413,941	\$ 14,985	0.28%	\$ 14,985	None
	Equity	Kunshan CDIB Yida Healthcare Enterprise Ltd.	-	Investment of equity instruments at fair value through other comprehensive income	-	\$ 57,968	2.37%	\$ 57,968	None

Note 1: Securities as stated in this table are the stocks, bonds, beneficiary certificates and the securities deriving from the above items within the scope of IFRS 9, "Financial Instruments"

Note 2: The Company determines the securities to be listed in accordance with the principle of materiality and does not disclose the securities with a carrying amount of less than NTD 1,000.

Cenra Inc. and subsidiaries

Purchase from or sale to related parties for an amount exceeding NTD100 million or 20% of paid-in capital

January 1 to June 30, 2025

Attached table 4

Unit: NTD thousand

Purchase (sale) company	Name of counterparty	Relation	Transactions				Trading terms different from general trade and reasons		Notes and accounts receivable (payable)		Remarks
			Purchase (sale)	Amount	Percentage of total purchase (sale)	The credit period	Unit price	The credit period	Balance	Percentage of total notes and accounts receivable (payable)	
China Chemical & Pharmaceutical Co., Ltd.	Chunghwa Yuming Healthcare Co., Ltd.	Subsidiaries	Sale	\$ 1,432,188	67.17%	The payment term is 150 days	Agreed by the quotation in the purchase agreement signed by both parties.	The payment term is 150 days.	\$ 1,754,784	75.33%	

Note: Individual accounts payable transactions less than NTD100,000 will not be disclosed.

Cenra Inc. and subsidiaries

Accounts receivable from related parties for an amount exceeding NTD 100 million or 20% of paid-in capital

June 30, 2025

Attached table 5

Unit: NTD thousand  
(Except where otherwise stated)

The company booked in the receivables	Name of counterparty	Relation	Receivables from related party	Turnover rate	Overdue Receivables from related parties		Receivables amount collected from related parties subsequently	Amount of provision for bad debts	Remarks
					Amount	Process			
China Chemical & Pharmaceutical Co., Ltd.	HU-YU Co., Ltd.	The Chairman is the same person of The Company.	\$ 264,127	0.48	\$ 158,286	To obtain the proven guarantee from the chairman of The Company and take joint and several liability for the unpaid debts or bills.	\$ 3,441	\$ 39,584	
"	Chunghwa Yuming Healthcare Co., Ltd.	Subsidiaries	1,754,784	1.65	551,921	Active debt collection.	298,349	-	

Centra Inc. and subsidiaries

Business relationships and significant transactions between parent company and subsidiaries

January 1 to June 30, 2025

Attached table 6

Unit: NTD thousand  
(Except where otherwise stated)

No. (Note 1)	Trader's name	Counterparty	Affiliation to trader (Note 2)	Transactions			Percentage in consolidated total revenue or total assets (Note 3)
				Title	Amount	Terms and conditions	
1	CCPC	Chunghwa Yuming Healthcare Co., Ltd.	3	Sale	\$ 1,432,188	Note 4	32.83%
1	CCPC	Chunghwa Yuming Healthcare Co., Ltd.	3	Accounts receivable	1,754,784	Note 4	14.21%

Note 1: The information about transactions between parent company and subsidiaries shall be numbered and noted in the following manner in the box of numbers:

- (1) Fill in "0" for parent company.
- (2) Subsidiaries are numbered from number 1.

Note 2: There are three types of relationships with traders, please mark the type intended:

- (1) Parent company vs. subsidiaries.
- (2) Subsidiaries vs. parent company.
- (3) Subsidiaries vs. subsidiaries.

Note 3: For computing the ratio of trade amount to total sales revenue or total assets, if it is for asset and liability account, the computation is based on the ratio of ending balance to total consolidated assets; however, if it is for income and expense account, the computation is based on the ratio of interim cumulative amount to total consolidated revenue.

Note 4: The selling price is agreed to by the quotation in the purchase agreement signed by both parties. The payment of the selling goods is 150 days.

Note 5: The significant matters between the parent company and subsidiaries have been written off.

Note 6: The amount of individual deal below NTD 100,000 will not be disclosed.

Centra Inc. and subsidiaries

The relevant information of names, area of location of the investees (excluding the investees in China)

January 1 to June 30, 2025

Attached table 7 Unit: NTD thousand  
(Except where otherwise stated)

Investor	Name of investee	Location	Principal business	Sum of initial investment		Ending shareholding			Current period profit / loss of the investee	Recognized investment Income	Remarks
				Current period-end	The end of last year	Number of shares	Ratio	Book value			
Centra Inc.	China Chemical & Pharmaceutical Co., Ltd.	Taiwan	Manufacture and sales of Western medicine preparations and health-care articles.	\$ 6,747,063	\$ 7,435,548	234,890,949	100.00	\$ 6,824,649	\$ 315,037	\$ 208,587	Subsidiaries
Centra Inc.	Providence Investments Inc.	Taiwan	General investment businesses	25,000	-	2,500,000	100.00	25,000	-	-	Subsidiaries
Centra Inc.	Chunghwa Yuming Healthcare Co., Ltd.	Taiwan	Wholesale of medicine and medical equipment	688,485	-	29,590,000	100.00	688,485	-	-	Subsidiaries
China Chemical & Pharmaceutical Co., Ltd.	Tairung Enterprise Co., Ltd.	Taiwan	Manufacture and sales of glass, plastics made containers	226,920	226,920	4,376	71.64	84,723	( 2,514)	-	Sub-subsidiary (Note 1)
China Chemical & Pharmaceutical Co., Ltd.	Chunghwa Holding Co., Ltd	Cayman Islands	Professional investment company	910,384	910,384	44,485,000	100.00	1,066,736	( 58,537)	-	Sub-subsidiary (Note 1)
China Chemical & Pharmaceutical Co., Ltd.	Chunghwa Senior Lifestyle Services Co. Ltd.	Taiwan	Medicine, wholesale of medicine equipment and home care service	354,400	354,400	5,000,000	100.00	( 834)	( 8,598)	-	Sub-subsidiary (Note 1)
China Chemical & Pharmaceutical Co., Ltd.	Sino-Japan Chemical Co., Ltd.	Taiwan	Manufacture and selling of the chemical materials	37,474	37,474	318,216	21.99	486,162	96,792	-	Evaluation of equity method
China Chemical & Pharmaceutical Co., Ltd.	Chunghwa Chemical Synthesis & Biotech Co., Ltd.	Taiwan	Manufacture and selling of the chemical materials	563,849	563,849	21,575,064	28.05	962,543	( 60,014)	-	Evaluation of equity method
China Chemical & Pharmaceutical Co., Ltd.	PHERMPEP CO., LTD.	Taiwan	Wholesale of biotechnology services and health products.	54,480	54,480	3,311,000	41.39	2,093	( 4,511)	-	Evaluation of equity method
Chunghwa Yuming Healthcare Co., Ltd.	Chunghwa Biomedical Technology Corp.	Taiwan	Manufacturer of cleaning products	17,680	17,680	1,768,000	75.23	18,129	4,805	-	Sub-subsidiary (Note 1)
Suzhou Chung-hwa Chemical&pharmaceutical Industrial Co., Ltd.	Chung-Hwa Le Huo Jian Kang (HK) Co., Ltd.	Hong Kong	Biotech products sold as an agent	-	-	-	100.00	-	-	-	Sub-subsidiary (Note 1)

Note 1: The Company does not recognize investment profit and loss directly.

Note 2: For the relevant information about the significant deals of the investees; Please see attached table 1-6.

Cenra Inc. and subsidiaries  
Basic information- Information of the investees in China  
January 1 to June 30, 2025

Attached table 8

Unit: NTD thousand  
(Except where otherwise stated)

Names of investees in China	Principal business	Paid-in shares Capital	Mode of investments (Note 1)	Accumulated amount of investment remitted from Taiwan at beginning	Amount of investment remitted or recovered in current period		Accumulated amount of investment remitted from Taiwan at ending	Current period profit / loss of the investee	The Company's directly or indirectly invested shareholding	Investment Profit or Loss for Current Period (Note 2)	Book value of investment at ending	The investment income received at the end of the current period	Remarks
					Outward remittance	Recover							
Suzhou Chung-hwa Chemical&pharmaceutical Industrial Co., Ltd.	Manufacture and sales of pharmaceutical medicine and health products.	\$ 755,151	2	\$ 768,672	\$ -	\$ -	\$ 768,672	\$ (58,527)	100	(\$ 58,527)	\$ 1,068,926	\$ 472,412	Note 1 (2), Note 2(2)B and Note 7
Suzhou Chunghwa Yuming Pharmaceutical Co., Ltd.	Wholesale and sales of pharmaceutical medicine and medical equipment.	132,149	3	-	-	-	-	( 23,528)	100	-	12,023	-	Note 2(2)C, Note 3 and Note 7
Shanghai Yuhou Trading Co., Ltd. (formerly known as Pei Fu (Shanghai) Co., Ltd.)	Wholesale and sales of medical equipment.	200,070	3	-	-	-	-	( 236)	100	-	6,807	-	Note 2(2)C, Note 4 and Note 7
Suzhou Chung-hwa Le Huo Jian Kang Co., Ltd.	E-commerce sales of health products	87,156	3	-	-	-	-	( 6,236)	100	-	21,494	-	Note 2(2)C, Note 5, Note 7
Wuxi Jirui Medical Technology Co., Ltd. (Wuxi Jirui)	Production and sales of APIs	23,451	3	-	-	-	-	( 6,640)	34	-	1,891	-	Note 2(2)C, Note 6, Note 7
Company name	Accumulated investment from Taiwan to Mainland China at ending	Amount of investment approved by Investment Commission of MOEA	Investment amount approved by the Investment Commission MOEAIC										
China Chemical & Pharmaceutical Co., Ltd.	\$ 296,260	\$ 769,143	\$ 4,160,516										

Note 1: There are three types of investments labeled by the respective number:

- (1) Direct investment in Mainland China.
- (2) Indirect investment in Mainland China through a third country (please specify the investment company in the third country)  
Investment in Suzhou Chung-hwa Chemical&pharmaceutical Industrial Co., Ltd. through Chunghwa Holding Co., Ltd.
- (3) Other ways.

Note 2: Recognized as gains or losses on investment in current period:

- (1) Please note if the investee is still under preparation and there was no investment gain or loss.
- (2) The basis of recognition of investment income is classified into following three types, which should be marked out.
  - A. Financial statements audited and audited and attested by an international accounting firm that has a cooperative relationship with a certified public accounting firm registered in the Republic of China.
  - B. Financial statements audited by the CPAs who audit the parent company in Taiwan.
  - C. Others.

Note 3: Direct investment with RMB 30,000 thousand by Suzhou Chung-hwa Chemical&pharmaceutical Industrial Co., Ltd.

Note 4: Up to 100% equity of Shanghai Yuhou Trading Co., Ltd. (formerly known as Pei Fu (Shanghai) Co., Ltd.) was purchased with a fund of RMB 1,797 thousand from Suzhou Chung-hwa Chemical&pharmaceutical Industrial Co., Ltd. in June 2016. In 2023, a total of RMB 41,278 thousand from Suzhou Chung-hwa Chemical&pharmaceutical Industrial Co., Ltd. was used for direct investment.

Note 5: Direct investment with RMB 20,000 thousand by Suzhou Chung-hwa Chemical&pharmaceutical Industrial Co., Ltd.

Note 6: Acquired 34% shareholding of Wuxi Jirui Medical Technology Co., Ltd. by use of RMB1,802 thousand capital from The Suzhou Chunghwa Yuming Pharmaceutical Co., Ltd.

Note 7: The Company does not recognize investment profit and loss directly.